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ABSTRACT 
Compression bandaging improves rates of healing in people with venous ulceration. 
Some ulcers appear resistant to compression therapy and may benefit from 
adjunctive therapy. Pentoxifylline is known to improve circulation, but individual 
trials have failed to conclusively demonstrate its effectiveness in venous ulceration. 
The objective of this meta-analysis was to assess the effectiveness of pentoxifylline as 
an adjunct to compression bandaging in the treatment of venous leg ulcers. 
The CENTRAL registers of the Cochrane Peripheral Vascular Diseases and Wounds 
Groups were searched - each register is routinely updated by extensive searches of 
electronic databases, handsearching of relevant journals and conference proceedings, 
and contact with product companies and experts in the field. The drug's 
manufacturer was contacted and the references of review articles and all obtained 
trials were scrutinised for further citations. 
Randomised controlled trials published in any language comparing pentoxifylline and 
compression with placebo in adult participants with venous ulceration were included. 
Trials must have reported a meaningful objective outcome (rates of healing, 
proportions healed, time to healing). Details from eligible trials (independently 
selected by two reviewers) were extracted and summarised by one reviewer. A second 
reviewer independently verified extracted data. 
Eleven clinical trials were identified. Five trials compared pentoxifylline with placebo 
(compression standard therapy). Six trials were excluded. Pentoxifylline and 
compression was more effective than placebo and compression (RR 1.30, 95% C1 
1.10-1.54) and was robust to sensitivity analyses. The greater number of adverse 
effects (46 reports) occurred in the pentoxifylline group, although this was not 
significant @R 1.12, 95% C1 0.77-1.62); 34 percent of adverse effects were gastro- 
intestinal. Seven of 21 reported withdrawals were for adverse effects. 
In conclusion, pentoxifylline appears an effective adjunct to compression bandaging 
in the treatment of venous ulcers. The absence of cost-effectiveness data suggests it 
not be employed as a routine adjunct, but it could be considered as for those patients 
not responding to compression therapy alone. The majority of adverse effects are 
likely to be tolerated by patients. 
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Chapter 1. INTRODUCTION 
Approximately 1 percent of the population are thought to have leg ulcers at some 
point during their lives (Dale, Callam, Ruckley, Harper, & Berrey, 1983). Widmer 
(1978) found 1.3 percent of 4376 adult workers in the Basle chemical industry had 
suffered or were currently suffering from leg ulcers. Leg ulcers are defined as a defect 
in the skin, below the level of the knee, persistent for 4 weeks or longer (Baker, 
Stacey, Jopp-McIGy, Hoskin & Tl~ompson 1991), although Nelzbn, Berqvist, and 
Lindhargen (1991) use 6 weeks as the threshold of chronicity. These definitions may 
also include isolated foot ulcers. Ulcers of venous aetiology are also known as 
varicose ulcers, stasis ulcers and gravitational ulcers. This chapter explores the 
prevalence of leg ulceration and venous leg ulcers, the causative mechanism of 
venous ulceration, the socioeconomic impact of leg ulceration and treatment options 
for people with venous ulcers. 
Epidemiology of Leg Ulceration 
Callam, Ruckley, Harper, and Dale (1985) investigated active leg ulceration in two 
Scottish Health Board areas encompassing a population of one million people. 
Surveys were posted to all general practitioners, district nurses, occupational health 
nurses, outpatient clinics, acute and long-stay hospital wards, old people's homes and 
physiotherapy departments, with returns cross-checked to ensure duplicate reports 
were not counted. A total of 1477 people were identified as having leg ulcers, giving 
a point prevalence for active ulcers of 1.48/1000, with prevalence increasing with the 
age of the population. Lees and Lambert (1992) also used a postal survey, dismbuted 
to district nurses with a caseload of patients with ulcers within an urban area 
encompassing a population of approximately 240,000. Eighty-four percent of nurses 
replied, reporting 206 patients aged 45 or more, currently being treated for 
ulceration. This converted to a prevalence of 1.9/1000; the authors also reported the 
incidence as 3.5/1000.' In relying upon patients being known to health workers (thus 
failing to estimate those self-caring) and focusing only on active ulceration (thereby 
excluding those people who were 'between' ulcers), these studies are likely to have 
underestimated the true prevalence of leg ulceration. 
1 Prevalence is the percentage of a population with target disorder; incidence is the proportion of new 
cases in the population with the target msorder (Sackett, Haynes, Guyatt, and Tugwell, 1991). 
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Venous disease, in the form of superficial or deep venous insufficiency, is thought to 
be causative of the majority of leg ulcers. Early reports were descriptive, relying on 
clinical history and examination to determine aetiology. Anning (1954) reported a 
case series of 1026 patients with ulcers, identifying venous disease as causative in all. 
Cornwall, Dore and Lewis (1986) randomly selected 150 people from a cross-section 
study investigating the prevalence of leg ulcers. Sixty-seven percent accepted the 
invitation to have an assessment and non-invasive physical investigation of the 
aetiology of their leg ulcer.' They found thirty-one percent had ischaemia, and ten 
percent had other aetologies, leaving the reader to intuit that fifty-nine percent of the 
sample had a venous causation of their leg ulcer. Callam, Harper, Dale, and Ruckley 
(1987), using a similar approach, investigated the aetiological distribution of 600 
participants from a previous sampling frame of 1477 people with open leg ulcers 
(Callam, et al., 1985). They found 76 percent had evidence of venous disease, 22 
percent had aaerial insufficiency, and 5 percent diabetes. 
Only two published studies have systematically investigated the aetiology of leg ulcers 
in a cross-section of defined populations. Baker, et al. (1991) sampled the population 
of Perth3 over a three-month period, drawing participants from self-referral, 
institutions, and health professionals. All participants provided a clinical history, and 
underwent a physical assessment including a non-invasive vascular examination by 
photoplethysmography. The investigators found 259 people with a chronic ulcer4, 
ninety-three percent (242 participants) of whom consented to be assessed. An 
abnormal refilling time was found in 138 participants (with 163 ulcerated legs), 
representing fifty-seven percent of the  ample.^ The investigators assumed the 242 
participants to be representative of all those identified with ulcers, and calculated the 
prevalence of chronic venous ulceration as 0.62/1000, with prevalence increasing 
with age (Table 1). It should be noted that this included a very small number of foot 
ulcers, determined to be of venous origin. 
"sing photoplethysmography and Doppler ultrasound. Photoplethysmography examines the 
competence of valves in the venous bed, while Doppler ultrasound is used to determine the Ankle- 
Brachal Pressure Index. 
' E s h a t e d  population 238,000 in June 1988. 
% ulcer was defined as a defect in the dermis below the knee, including foot ulcers, lasdng for 4 or 
more weeks. 
S A refd time less than twenty seconds, as determined by photoplethysmography is considered 
indicative of venous insufficieilq (Porter, et d., 1988), although Baker, et al. haw used a more 
conservative tweny-five seconds as the threshold. 
Table 1: Pmvalence of chmnic uenous ul~ration related t o  age and sex; adqted fmm Baker, e t  aL 
(1991) 
Male Female 
Age Number Prevalence Number Prevalence 
Nelzin, et al. (1991) aimed to identify all people with current leg ulcers, including 
foot ulcers, known to health professionals within a defined population of 270,800 in 
Sweden. Eight hundred and twenty-seven people were identified, and half of this 
group was randomly sampled to attend a clinical examination, consisting of a history 
and physical assessment with Doppler ultrasonography, to determine ulcer aetiology. 
Ninety-two percent of the sample accepted the invitation to participate and this 
group corresponded with the original sample on age and sex distribution. All 
participants were examined by the same clinician and the aetiology was recorded as 
one of eleven categories (Table 2, seepage 4). Fifty-four percent of the 382 participants 
were determined to have ulcers of primarily venous aetiology6, giving a point 
prevalence of 1.6/1000 (95% confidence interval 1.5-1.8/1000). Ninety-five percent 
of the ulcers were on the gaiter area of the leg, excluding the isolated foot ulcers 
increased the percentage of venous leg ulcers from fifty-four percent to seventy 
percent. As with Baker, et al. (1991), prevalence of ulceration increased with age. 
Nelzkn, et al. (1991) explain the greater prevalence in their study as being a factor of 
population difference; the percentage of the population older than 65 was 18.4 
percent in the Swedish study compared to 12.4 percent in Baker, et al. (1991). 
However, both Baker, et al. (1991) and Nelzin, et al. (1991) believed they have 
under-reported the true prevalence of ulceration. Neither study attempted to estimate 
the numbers of people 'between' ulcers, and whilst Baker, et al. (1991) attempted to 
accrue people who might be self-caring of their ulcers through a newspaper article at 
W c e r s  in legs with ultrasonic proof of reflux in the venous bed and absence of any other major 
aetiological factor. 
the start of the study period, this was not followed up over the course of the study. 
Nelz&n, et al. (1991) only approached health professionals to identify those with an 
open ulcer and did not attempt to determine 
Table 2: Causes of leg ulcen @ercentages mundedj; adqbtedjbm Nel$n, et al. (1991) 
Aetohgic G m q  AL Ulcers Ulcers above thejbot 
Venous 184 (40) 182 (52) 
Mixed venous/arterial 66 (14) 65 (18) 
Mixed arterial/venous 20 (5) l 5  (4) 
Arterial 34 0 l 3  (4) 
Arterial/diabetes 43 (9) 5 (2) 
Diabetes 18 (4) 2 (1) 
Traumatic 9 v-') 8 (2) 
Pressure 15 (3) 1 (<l) 
Multi-factorial 48 (11) 40 (11) 
Other single causes X, (6) D (6) 
numbers of people who might be self-caring. Thus, the true extent of the problem is 
still concealed, hidden by the methodological approaches of recent attempts to 
quantify the prevalence of leg ulceration, the desire of some people to care for their 
own ulcer, and possibly by the variety of health professionals who care for patients 
with leg ulcers7 (Ruckley, 1997). 
Causation of Venous Leg Ulcers 
Hippocrates is said to have recognised the relationship between ulceration and 
superficial varicosities 2000 years ago, as did the Roman physicians Aurelius 
Comelius Celsus, Claudius Galen and Aetios of Amida (Negus, 1995). With the rise 
of the humoral theory in the Dark Ages, ulcers were thought to be caused by the 
efflux of dangerous humours, but this theory began to lose ground from the 
seventeenth century, as the understanding of thrombus formation began to be 
understood.' John Gay introduced the term 'venous ulcer' and described the role of 
' Plastic surgeons, vascular surgeons, dermatologists, rheumatologists, geriaaicians, general 
practitioners, nurse specialists and district nurses. 
B Rudolph V ~ n h o w  first used the term fibrinogen and described his triad of the causes of thrombi in 
1860. 
damage to the deep veins by thrombus formation in 1868 (Browse & Burnand, 1982; 
Negus, 1995). This theory found few adherents, but was revived by John Homans in 
1917, who noted that few venous ulcers occur in the presence of varicose veins and 
described the destruction of venous valves by thrombus formation9 (Negus, 1995). 
Thrombosis destroys the deep veins, leaving either, narrow irregular and valveless 
channels if the vein recanalises, or tortuous dilated collateral veins with incompetent 
valves if the deep vein does not recanalise (Browse, 1983). 
When the legs are in a dependent position, a significant volume of blood is held in 
the venous bed of the leg, 100-140ml in the sinusoids alone. This is approximately 
equivalent to that held in the heart (Negus, 1995). Quietly standing, without any 
movement of the legs, the muscles of the lower extremity rhythmically contract and 
relax, ejecting blood from the superficial venous system into the deep veins, the 
sinusoids of the gastrocnemius and soleus muscles, and then into the proximal veins, 
aiding venous return to the heart. It is thought that this pumping action, although 
not required to maintain venous return to the heart, "is gv i ta l  i@ortance topreserve the 
integn'ty ofthe micmcirculadon, by rehcing dstal capillmypressure when standing" (Stranden & 
Kroese, 1995, p59). The venous pumps are located in the thigh (quadriceps, sartorius 
and hamstring pumps), and most importantly, in the calf muscles. During the systole 
of the calf pump, competent valves in the deep and communicating veins protect the 
superficial venous system from the high contractile pressures of up to 250mmHg10 
within the muscle. In the absence of any pathology, this is seen in ambulatory venous 
hypotension during exercise, where the pressure in the dorsal vein of the foot falls 
from 90mmHg to 20mmHg (Negus, 1995). The valves also prevent backflow during 
the diastole, and the veins are refilled. Without the venous pumps acting as a 
compensatory mechanism, severe capillary distension would occur from exposure to 
high pressures during the systole of the calf pump (ibid.). Obstruction of the deep 
veins by thrombi, or destruction of the valves in the communicating or deep venous 
systems may reverse the blood flow from superficial to deep to proximal veins on 
exercise, leaving the superficial veins distended by high pressure throughout exercise 
by ambulatory venous hypertension. 
Despite the knowledge that venous ulcers occur in the presence of calf muscle pump 
' Traricose veins in the absence of any deep venous damage are termed superficial venous 
insufficiency. 
deficiencies, the mechanism by which the ulceration occurs is unknown. The two 
principle explanations of the early to mid-twentieth century, venous stasis and 
arterio-venous shunting, have been rejected. Browse and Burnand (1982) noted that 
venous stasis, or stagnant blood lying close to the skin causing tissue anoxia was 
debunked by the finding that oxygen saturation in the blood of venous ulcers was 
higher than in the non-affected limb of participants. The higher oxygen content and 
faster blood flow observed in venous ulcers was then considered to be the result of 
shunting through microscopic fistulas between arterioles and venules, resulting in 
anoxia of the overlying tissues. However, Browse and Burnand (1982) observed that 
examination of people's ulcers with radioactively labelled macroaggregates had failed 
to show any such fistulas, and therefore proposed a new hypothesis (Browse & 
Burnand, 1982; Browse, 1983). They had noted that skin biopsies of patients with 
deep venous insufficiency showed fibrin cuffs around the capillaries. Browse and 
Burnand (1982) suggested that the venous hypertension increased the intraluminal 
pressure of capillaries, stretching the interendothelial pores, and allowing large 
molecules such as fibrinogen to escape into the interstitium at greater than normal 
rates. This was converted into fibrin, but the abnormal volumes exhausted the 
fibrinolyac activator, allowing the creation of pericapillary fibrin cuffs which 
prevented the diffusion of oxygen, leading to tissue anoxia, cell death and ulceration 
(Fkure 1, seepage 7) .  
Other investigators have proposed a theory that incorporates fibrin cuff formation, 
but advance that this is not the causative mechanism of ulceration, only a by-product 
of the aggregation of white blood cells. Coleridge Smith, Thomas, Scurr and 
Dormandy (1988) noted that there is no evidence that a fibrin cuff is a barrier to 
diffusion, and that other investigators had found areas of skin under capillary 
fluorescence microscopy with no apparent blood flow. They hypothesized that the 
slowing of venous perfusion by hypertension caused the capillaries to become 
plugged by white cells. The trapped white cells release proteolytic enzymes and 
superoxide radicals resulting in endothelial damage. This causes the increased 
permeability with the consequent loss of fibrinogen and formation of a fibrin cuff. 
However, Coleridge Smith, et al. (1988) hypothesize it is the trapped white cells that 
prevent circulation in the affected capillaries with the subsequent anoxia resulting in 
tissue death in the area surrounding the capillaries (Figure 2, seepap 8). Mirshahi, 
l0 mmHg represents pressure measured in millimetres of mercury. 
I High ambulatory pressure in calf muscle pump 1 
Transmitted through 
communicating to superficial 
system 
Distend capillary bed and widens 
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Figure 1: Cycle f causative mechanism of yenous ztllceration; a@ted j'm 
Bumand (1982). 
Soria, Mirshahi, Soria, Lenoble, Vasrnant, Cambazard and Claudy (1995): 
blind randomised controlled trial of 10 people with venous ulcers, found 
of fibrin and elastase (an enzyme released by activated white cells) il 
treated with pentoxifylline. Pentoxifylline is known to reduce 
aggregation and fibrinogen loss (Stellin & Waxman, 1989). The authors concluded 
this evidence was supportive of the white cell irapping theory, and suggested that 
'iny7amation generated ly activated u~hzte blood celh that accumulate with unrebeved uenous 
pressure is thejrst event in chronic leg ulcer" (ibid. pS105). 
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Figure 2: Cycle cfcausative mecha?lism of uenous ulceration; adqbtedfmm Coleridge Smith, e t  
al. (1988). 
Socio-economic Impact of Venous Ulceration 
The impact of ulceration on perceived health is considered in terms of quality of life. 
There are few studies available in English that have examined this aspect of leg 
ulceration, fewer still that have examined the problems confronted by people with 
venous ulceration (Lamping, 1997; Ruckley, 1997). However, Lamping (1997) notes 
that quality of life studies are assuming more importance because the traditional 
definition of health has broadened to incorporate physical, mental and social well- 
being, health interventions are recognised to have an effect on other outcomes than 
morbidity and mortality, and purchasers are demanding increased evidence of cost- 
effectiveness in terms of health outcomes meaningful to patients. Quality of life 
(QoL) has been studied using well-validated generic tools, as well as qualitative 
studies. The Short Form Health Survey-36 (SF 36) has been used in one study (Price 
& Harding, 1995; Price & Harding 1996), whilst the Nottingham Health Profile 
(NW) has been used in three studies, two in Britain and one in Sweden (Lindholm, 
Bjellerup, Christensen, & Zederfeldt, 1993; Hamer, Cullum, & Roe, 1994; Franks, 
Bosanquet, Brown, Straub, Harper, & Ruckley, 1999). The richer texts of the 
descriptive and the qualitative approaches provide the existential narratives of people 
living with chronic ulceration, which despite non-probability sampling techniques, 
are consistent with the data of the quantitative approaches (Phillips, Stanton, Provan, 
& Lew, 1994; Charles, 1995; Walshe, 1995; Chase, Melloni, & Savage, 1997). 
Price and Harding (1996) used the SF-36 to assess 55 patients, 37 women and 18 
men, against age-equivalent norms on eight sub-scales." The patient group rated 
themselves more poorly on all sub-scales except for mental health '%onfirming cknical 
i@ressions that thesepatients have a condtion that gects the Q o L "  (ibid., p445). The male 
participants rated themselves as significantly healthier than the women on physical 
functioning @=0.006), vitality (p=0.028) and social functioning @=0.017). The 
authors also note that when followed up 4 months later, the self-ratings had not 
changed significantly despite the ulcers having healed in 35 percent of the patients. 
Price and Harding suggest that this may be a limitation of the generic measures of 
health-related quality of life (HRQoL), and that disease-specific tools should be 
developed for people with chronic wounds. Studies using the N W  also found that 
" The 8 subscales ofthe SF-36 are physical functioning, social functioning, role limitation (physical), 
role limitation (emotional), pain, vitality, general health perception md mental health. 
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people with chronic ulcers are burdened by their ulcer. Lindholm, et al. (1993) 
administered only part 1 of the two part NHP questionnaire12 to 154 consecutive 
patients with venous, mixed aetiology and arterial ulcers attending a Department of 
Dermatology clinic over 13 months. One hundred and twenty-five questionnaires 
were evaluated. The mean global score was 173 percent of normal (age and sex- 
adjusted), indicating significantly lower perceptions of well-being. These scores 
varied considerably between men and women, with men scoring lower on perceived 
health (232 percent of normal) than women (132 percent of normal), thus 
contradicting the findings of Price and Harding (1996).13 Lindholm, et al. (1993) 
found men scored higher than women on every parameter, and globally men and 
women scored higher than normal on each parameter. The exception was that the 
women with ulcers scored normal on social isolation. 
Franks and Moffatt (1998) noted that the gender difference observed by Price and 
Harding (1996) was reversed in the study by Lindholm, et al. (1993), and 
hypothesized that this was a consequence of Price and Harding (1996) using raw 
scores, whereas Lindholm, et al. used expected age/sex adjusted values of the normal 
population?4 Franks and Moffatt (1998) tested 758 people with leg ulcers that had 
been identified by a previous prevalence survey using the NHP. They found the 
pardcipants had significantly higher NHP scores on all six scales, indicating poorer 
perceived health-related quality of life than age/sex matched normal values. 
Increasing age lead to greater deficits in energy, mobility and social isolation. Using 
raw scores, women had lower perceived HRQoL than men, but this would be 
expected as 64% of the sample were women and the sample became more skewed 
towards women as the age of the participants increased. When scores were adjusted 
for age/sex matched normal values, it was the younger people that had the greatest 
deficit in perceived HRQoL in all domains and men had lower perceived HRQoL 
than women in the domains of bodily pain, sleep and social isolation and energy. 
Q The 6 mas  rated in the Nottingham Health Profile are pain, physical mobility, sleep, energy, 
emotional reactions and social isolation. 
1' It should be noted that Price and Warding (1996) considered their study to be exploratory, rather 
than dehnitive. 
l4 Franks and Moffatt (1998) also suggested the difference may be as a consequence of fundamental 
differences between the two populations and that the studies used different tools that have subtle 
variations in scoring. However, the authors believed the difference most likely derived from the use of 
controls or age and sex matched normal values. 
A descriptive quantitative study using standardised interviews reinforces the findings 
of the HRQoL studies using generic questionnaires. Phillips, et al. (1994) interviewed 
62 people (25 men and 37 women) about the financial, psychological, functional and 
emotional impact of leg ulceration. They found that 81 percent believed their 
mobility was adversely affected, with men reporting more immobility than women; 
that in 42 percent of those not working, ulceration was a factor in the decision to 
stop working, and that in all participants still working, their work capacity was limited 
by ulceration. Sixty-five percent of participants reported severe pain associated with 
their ulcer and 68 percent said the ulcer had a negative emotional impact, with the 
variety of emottons being fear, social isolation, anger, depression and negative self- 
image. This was significant in younger people "who tended t o  be more depressed about thezr 
condition and have a more negative se&iimgee" (Phillips, et al., 1994, p52). Despite the fact 
that 71 percent had other severe medical problems, such as hypertension and cardiac 
disease, all participants believed that their leg ulcer was their most significant 
problem. Multivariate analysis revealed that the primary concerns of the participants 
were the ability to walk, accomplish everyday tasks and maintain mobility. 
The above studies included participants with ulcers of any type in their samples. 
Three phenomenological studies focused on the experiences of people with venous 
leg ulceration, with remarlrably consistent results (Charles, 1995; Chase, et al., 1997; 
Walshe, 1995). Chase, et al. (1997) identified 4 major themes from interviews with 7 
patients - 'a forever healing process', 'limits and accommodations', 'powerlessness' 
and iyho cares? A 'forever healing process' related to patients having had extensive 
histories of ulceration, with half not able to remember their frst  episode. Healing no 
longer had the positive connotations of overcoming an acute illness; healing comes 
to mean a constant attention to the positive and negative changes in the body, and a 
constant need for health care. It  is not an isolated episode of professional care and 
attention, '?it's like a f o r e ~ r  healingpmcess, notgetting uorse, notgethng better" (Chase, et al., 
1997, p74). The second theme identified by Chase, et al. was 'limits and 
accommodations'. Participants described major limitations in activity as a 
consequence of pain and mobility impairments: "I cannot do anything I want. I cannotgo 
any place . . . I kind $got used to it" (ibid. p75); 'Feople can't believe thepainyou haue with an 
ulcer" (Charles, 1995, p574). Lifestyle limitations were also a result of job loss, 
treatments and self-imposed resmctions. Negative body images associated with open 
wounds meant that many participants reported the need to hide their bodies, with 
clinics being the only place participants were told their legs looked good. Both 
Charles (1995) and Walshe (1995) report the restrictions caused by immobility and 
participants' need to disguise or hide their ulceration: '7 couldn't stand and do things like 
housework. I ued to he a competitive swimmer before I had the ulcer. I didn't swim anj more, not 
even m'th my children" (Charles, 1995, p574). This theme has significant impact on 
human interaction, with social isolation increasing, especially as participants drop out 
of the workforce, or age. 
Chase, et al. (1997) described the third theme as 'powerlessness', revealed in the 
effects of slow wound healing and the likelihood of recurrence, and patients not 
being able to control the healing outcome. One participant described his ulcer as 
running his life: '7 have to take more cm ofmyfoot than I have t o  take care ofmysey (Chase, 
et al., 1997, p76). Participants quoted by Walshe (1995) described this as the 
uncertainty of healing, reinforced by the lack of a known timescale, whereas Charles 
described this as hopelessness, helplessness and lack of control: 'Tt bmke down evely 
year. Everyyear at the same qot. Itgradual4 got bz&er and then stged the same s i ~ "  (Charles, 
1995, p574). Even patients, who had an internal locus of control, usually associated 
with an active approach to problem solving, were worn down by the 'forever healing' 
and came to believe they had no control over ulceration (ibid.). The fourth theme, 
'who cares? describes both who treats and manages the participant's ulcer Some 
participants managed their own ulcers, although neither Charles (1995) nor Walshe 
(1995) report this. Walshe does note that participants tended to hand over control of 
their treatments to professionals and rarely were included in the care. Charles 
expands this theme to incorporate concerns about whether health workers actually 
care about their patients or know what they are doing: 
In hoqital, a t jrs t  the sister took me into the dt~ssing mom and pointed to seyeral 
applications She stopped at @duct A], andfor threeyears I was stuck with bmdud 
A]. You are just a number, another tin o f  baked beans, t h y  walk you in, dress you 
and walkyou out. 
(Charles, 1995, p574) 
The economic impact of venous leg ulceration is considered significant, but has 
mainly been reported as a cost to the health system. Only one study has considered 
the economic impact on those afflicted with leg ulceration, venous or otherwise. 
Phillips, et al. (1994) reported both the impact of ulceration on work capacity as well 
as patient estimates of annual costs they bear for ulcer treatment. Leg ulceration was 
significantly correlated with time lost from work and job loss. Expenses incurred 
included costs of medical care, time lost from work, cost of dressing and 
transportation costs.'' More than 30 percent of the participants reported costs of 
between $101 and $1000 per annum, with time lost from work being the smallest 
element of this. However, time lost from work was estimated at more $1000 per 
annum by 25 percent of participants. 
The cost to the health service of caring for people with venous ulceration in Britain 
has been estimated at between £230-£400 million at 1991 prices (Bosanquet, 1992). 
Laing has estimated that people with venous diseases utilised 1.5-2 percent of the 
total health care budgets in Britain, France and West Germany at 1992 exchange 
rates (in Ruckley, 1997). Harkiss (1985) estimated the 4 month costs for a variety of 
products used by community nurses to dress leg ulcers, as ranging from £132 to 
£1290. This figure was dependent on the type of product selected as well as the 
number of dressing changes per week. It did not include indirect costs such as 
nursing time or vehicle costs. More precise estimated costs are reported from 
randomised controlled trials. Franks, Bosanquet, Brown, Straub, Harper, and Ruckley 
(1999) found the total direct and indirect costs of treating 200 patients over 24 weeks 
to be approximately £193,000, with a cost per healed limb o f f  1654. The 41 percent 
of people whose ulcers remained unhealed after the mal concluded continued to 
represent a significant cost to the health service. Morrell, Walters, Dixon, Collins, 
Brereton, Peters and Brooker (1998), in a cost-effectiveness study of specialist ulcer 
service which achieved better healing rates than district nursing, estimated the direct 
and indirect costs of the ulcer service at £878 per patient per year compared to the 
'normal' treatment group f859.I6 Again the 44 percent of participants whose ulcers 
remained unhealed at the completion of the trial remained a cost to the health 
system. 
l' This study was conducted in the United States and estimated costs will reflect the American model 
of health care. 
'"he superior heding rates achieved by the specialist service compensated for the minor cost 
difference making the specialist ulcer service the more cost-effective service. 
Treatment of People with Venous Ulceration 
The therapeutic mainstay in management of venous ulceration is graduated 
compression bandaging, achieving pressures of 23mmHg at the ankle and decreasing 
as it ascends to the knee. A systematic review found high compression bandaging of 
any nature (3 layer, 4 layer or short stretch bandaging) achieved healing in larger 
proportions of people with venous ulcers than low compression bandaging or no 
compression (Cullum, Fletcher, Nelson, & Sheldon, 1999). Despite this many 
people's ulcers remain unhealed after 3 months of compression therapy, with the 
proportions of people with unhealed ulcers varying ranging from 25 to 60 percent 
(Hendricks & Swallow, 1985; IGtka, Schuler, Meyer, Durham, Eldrup-Jorgensen, 
Schwarcz & Flanigan, 1988; Charles, 1991; Duby, Hofman, Cameron, Dobloff- 
Brown, Cherry & Ryan, 1993; Wilkinson, Butterfield, Cooper, & Young, 1997). 
Adjunctive treaiments need to be considered for people with ulcers refractory to 
compression therapy. Such treatments include extended bedrest, split skin grafting, 
pinch grafting, hyperbaric oxygen therapy, as well as pharmacological treatments. 
One promising pharmacological agent is pentoxifylline. 
Pentoxifylline was developed by Albert-Roussel, a subsidiary of Hoechst AG. It is a 
xanthine derivative that has haemorrheolgical properties and first became available 
commercially in 1972, primarily for the treatment of intermittent claudication. 
Haemorrheology is a term coined in 1952 by Alfred Copley and is concerned with 
the flow properties of blood (Savitsky, 1986). Fluid mechanics is influenced by the 
interrelationship between the length and diameter of the tube through which a fluid 
is moving, the pressure within the tube and the viscosity of the fluid. Normally blood 
viscosity is low, but this can be increased by a greater percentage of erythrocytes in 
the plasma, a decrease in the rate of flow produced by an obstruction or the presence 
of abnormal levels of proteins in the plasma (Savitsky, 1986). 
Erythrocytes are approximately 8 microns in size and disc shaped when moving 
through major vessels, but must flex, bend or elongate to move through capillaries, 
which have a diameter of between three and five microns. Tissue ischaemia creates 
an anaerobic cascade, releasing lactic acid and causing local acidosis and 
hyperosmolarity. This seems to cause erthyrocytes to lose flexibility by decreasing 
intracellular adenosine triphosphate (ATP) and enhancing local hypoxia (Stellin & 
Waxman, 1989). Pentoxifylline has been shown to improve erthyrocyte flexibility by 
inhibiting erthyrocyte phosphodiesterase, thus increasing available ATP (Spittell, 
1986). More importantly with regard to microcirculatory causes of venous ulceration, 
pentoxifylline has been shown to influence leukocyte migration, decrease fibrinogen 
concentrations, and inhibit platelet aggregation. In low flow states, leukocytes are 
activated and adhere to capillary walls, releasing oxygen metabolites and proteolytic 
enzymes (Stellin & Waxman, 1989). Leukocytes, though smaller in number than 
erythrocytes (approximately 1:700), can significantly contribute to plasma viscosity 
(Ward & Clissold, 1987). Pentoxifylline destabilises polymorphonulcear leukocyte 
membranes, exposing the cell to chemotactic agents that encourage cell migration 
(Stellin & Waxman, 1989). Pentoxifylline also decreases plasma fibrinogen levels 
either through increasing fibrinolpc activity or decreasing the production of 
fibrinogen (Ward & Clissold, 1987; Stellin & Waxman, 1989). Mirshahi, et al. (1995) 
demonstrated that the expression of the enzyme elastase and creation of fibrin was 
reduced in people with leg ulcers, following treatment with pentoxifylline. This may 
be a result of the drug's action on leukocytes and fibrinogen. Pentoxifylline also 
inhibits the formation of thromboxane, a major stimulant to the aggregation of 
platelets, probably by inducing the synthesis and release of the precursor, 
prostaqclin (Spittell, 1986; Ward & Clissold, 1987). 
The therapeutic actions described above prompted investigators to research the 
effectiveness of pentoxifylline in the treatment of venous ulceration, as an adjunct to 
compression therapy. These studies, tending to small numbers, different outcome 
measures and methodological problems, have produced confusing results. Two of 
the larger studies produced a significant result in favour of pentoxifylline, and an 
insignificant result, in the direction of pentoxifylline (Colgan, Dormandy, Jones, 
Schraibman, Shanik, & Young, 1990; Dale, Ruckley, Harper, Gibson, Nelson, & 
Prescott, 1999). That conventional treatment using compression bandaging does not 
heal all people with venous leg ulcers means that other treatment modalities deserve 
investigation. Any adjunctive treatment that improves rates of healing may hold 
promise for those that do not respond to compression alone. Therefore, it is the aim 
of this investigation to use meta-analysis in order to determine whether pentoxifylline 
is effective at improving rates of healing for patients with venous leg ulcers. 
Chapter 2. METHODOLOGY 
Review articles are a necessary disciplinary tool "becuu~e t h y  deliberate4 aim at amdating 
knowhedge in an area" (Feldman, 1971, p86). The actual purpose may vary from review 
to remew. Reviews may attempt to explore the impact of developments in a field, 
verify existingtheories or develop new ones, synthesize knowledge from different 
lines, or infer generalisations about substantive hypotheses from a set of studies 
directly bearing on those hypotheses (Jackson, 1980). The subject of this chapter is 
reviews that meet Jackson's fourth purposes; those that attempt to draw 
generalisations from different studies that have tested a similar hypothesis. Such 
reviews are known by a variety of names: data pooling pooled analyses, integrative 
reviews, meta-analyses, met-analyses, quantitative review, research integration, 
research syntheses, research overviews, systematic reviews and systematic overviews 
paveggia, 1974; Glass, 1976; Glass, 1977; Jackson, 1980; Gerbag & Honvitz, 1983; 
Jenick, 1989; Dickersin & Berlin, 1992; Cooper & Hedges, 1994; Cook, Sackett, & 
Spitzer, 1995; Finney, 1995). Glass (1976) distinguishes such reviews from secondary 
analyses, which are the re-analysis of data for the purpose of re-evaluating data with 
better statistical techniques in order to better answer the original research question. 
Research synthesis is used as a generic term throughout this chapter and refers to the 
retrieval and analysis of results from individual studies for the purpose of integrating 
the studies' findings. Research synthesis can thus include both qualitative and 
quantitative methods of synthesis. 
It  is common to all literature reviews that they are not based on new facts, but that 
they utilise published material as a base and synthesize the information from previous 
publications in some manner (Cooper & Hedges, 1994). The review has become 
increasingly necessary because 
Virtzia4 eueryjeld o f  science is now pewded bJ, a nlentless cmssjin in which the 
jndings o f  new studies not on4 dzfferJmm previousEy established truths, bbztf disagree 
uith one another, often vehementb. 
(Hunt, 1997, pl) 
The role of the literature review has considerable potential for gate-keeping in 
professional practice, and as such standard, rigorous and replicable criteria should be 
applied to them (Cooper & Rosenthal, 1980). The most common type of review is 
probably the narrative review, in which the author gathers together studies around a 
topic, summarising them and arriving at a qualitative conclusion. However, the 
oppomnity for biased presentation is enormous in this type of review, through 
selective inclusion of studies, and subjective weighting and interpretation of the 
findings (Wolf, 1986; Gerbag & Horwitz, 1988; Hunt, 1997). Such reviews also 
cannot examine the characteristics of studies as potential reasons for disparate 
results, or examine for moderating variables in the relationship being reviewed (Wolf, 
1986). Furthermore, the generally implicit method of narrative review means that it 
cannot be reproduc.ed and thus is of limited merit scientifically (Gerbag & Horwitz, 
1988). 
Cooper and Rosemthal (1980) investigated the vulnerability of the narrative review, 
by presenting graduate students and faculty members with 7 articles, which were to 
form the basis of either statistical summation of effect size, or traditional narrative 
review. The participants were randomly assigned to groups and the investigators 
measured support for the hypothesis that 'Me evidence in general sqpoltr the conch6sion 
thatjmaLes a n  mon pem'stent, or bemme more involued in tasks, than males" (ibid., p444). 
They found that participants using the statistical technique perceived more support 
and a greater magnitude of effect than did the narrative reviewers, suggesting 
narrative reviews could gpte-keep by reflecting reviewers' own beliefs rather than that 
of the units of data. 
Antman, Lau, Kupelnick, Mosteller and Chalmers (1992) also addressed the issue of 
bias in a comparison of the results of a meta-analysis of randomised controlled trials 
(RCTs) and the recommendations of clinical experts in narrative reviews and 
textbooks on the treatment of acute myocardial infarction PI). The authors 
cumulatively combined the results of RCTs by year and compared the annual 
summary statistic to the advice contained in reviews and textbooks published the 
same year. They found that "n?view aeicles @en fdled to  mention iqortant adoances in 
tnatment or exhibited delcgs in ncommenrling effectiue preventive measures" (ibid., p240). 
Ineffective treatments or treatments that were harmful also continued to be 
recommended by some authors. For example, 6 years elapsed between the time a 
meta-analysis published in the New England Medical Journal first demonstrated the 
reduction in mortality associated with tl~rombolytic therapy post M1 (at p<0.001), 
and the time the majority of review authors recommended it. The authors believed 
that this and similar intervals could not be explained by the usual publication delays. 
Similarly, the authors found lignocaine, which has been recommended as a 
prophylactic for ventricular fibrillation throughout the last 25 years in textbooks and 
narrative reviews, was not supported by evidence of reduction in mortakty in trials. 
Mulrow (1987) had earlier investigated the overall rigor of review methods in 
medicine by examining 50 review articles drawn from four premier medical journals1, 
and evaluating them against 8 criteria drawn from guidelines on information 
synthesis.' Mulrow did not report how the articles were selected, but found that no 
review article met all criteria and only one review met 6 of the criteria. Qualitative 
synthesis'vras the commonest method of integrating the studies' conclusions, with 
just 3 reviews using quantitadve methods of synthesis. Mulrow identified steps that 
review authors could take to improve the quality of information syntheses in 
medicine and concluded that ''b using systematic methods of exploration, evaluation and 
synthesis, the good reviewers can accoqLsh the task of advancing scient$c knowledge" (Mulrow, 
1987, p487). Though considered a seminal work in health sciences, Mulrow owes a 
considerable although largely unacknowledged debt to the development of research 
synthesis as a research activity in the social sciences, especially sociology and 
psychology. 
The Development of Research Synthesis in the Social Sciences 
The need for advances in research synthesis was signalled by Feldman (1971), in a 
discussion of review methods and he proposed that the method of research synthesis 
was analogous to that of primary research. Thus 
Jjstematica4 reviewing and integrating what is nomina4 cahd the '7itemture" o f a  
field m q  be considered a we of research in its own night - one using a charaderistic set 
of research techniques and methods. 
(Feldman, 1971, p86) 
' Annals of Internal Medicine, Archives of Internal Medicine, Journal of the American Medical 
Association, and The New England MedicalJoun~al. 
"as a specific purpose stated? Were sources and methods of citation searches identified? Were 
explicit criteria provided that determined the inclusion or exclusion of studies? Was methodologic 
assessment of validity performed? Was information systematically integrated with explication of data 
limitations? Was the information integrated and weighted or pooled metrically? Was a summaty of 
pertinent findings provided? Weere specific directives for new research initiatives proposed? 
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Such reviews could act as a compendium of research relevant to a topic, simulating a 
broader sample than is usually possible in a single trial, and where study protocols are 
similar, simulate replication. Feldman concluded that a 'good integration' revealed 
not only how much is known, but also how little is known within a field; within this 
sense the integration is not an end, but a beginning. However, Feldman did not 
propose a method for research synthesis, although he did present an overview of 
potential methods and their problems. Feldman was not alone in raising the 
problems of reviews in psychology. Light and Smith (1971) had also identified the 
inadequacies of the then current methods of review and proposed that progress wiL2 
on& come when we a n  able topool, in a ystematic manner, the original data,fmm stiides (ibid., 
p443), rather than cumulating significance tests. They suggested the cluster approach 
for quantitatively synthesizing studies, a method that was similar in spirit to the soon 
to be developed effect size analysis, although more conservative (Glass, 1977). 
Within sociology, 'I'avegia (1974) had also identified 6 areas that were problematic 
for review.' More important was Tavegia's belief that review authors had failed to 
understand that research results are probahilistic. The findings of a single study may 
not be meaningful, as they could have occurred by chance. Thus, where a number of 
studies have been conducted on a given topic, any apparently contradictory fmdings 
may simply be the distribution of results, chance alone having dictated the negative 
and positive results. 
Synthetic methods for agregdting the results of independent but similar studies had 
received attention at various intervals throughout this century. The earliest work is 
probably that of Pearson in 1904, averaging the correlation between inoculation for 
typhoid fever and mortality in 5 studies (Cooper & Hedges, 1994). Broadly, the 
methods can be grouped into three approaches: vote counting, combined tests and 
measures of effect size (Wolf, 1986). Vote counting involves tallying study results 
into positive and negative significant results, and statistically insignificant results, and 
determining which category has a greater than one third of the studies. This category 
is then the fwinner'. Vote counting has been rejected as a synthetic method 
principally because the method's power is low and decreases with increasing numbers 
of studies, thereby increasing the probability of Type I1 error4 (Hedges & Olkin, 
1980). The method also assumes that the size of treatment effect within each study is 
The 6 areas were selection of articles; indexing, coding and retrieval of data; analysis of comparability 
of findings; cumulation of hndings; analysis of the resulting distributions; and reporting of results. 
4 Accepting the null hypothesis when it should be rejected. 
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the same in the binning' modal category, although this is rarely the case. The use of 
combined tests arose out of a desire to sum the results of independent studies. 
Rosenthal (1978) identified seven methods for summing significance levels. 
Examples are adding logarithms of p values (Fisher Combined Test), adding t tests 
(Winer Combined Test) or raw or weighted 7 tests (Stouffer Combined Test). These 
tests, however, only determine whether the aggregated statistic is significant and do 
not provide an indication of the strength of the relationship or size of effect of a 
treatment. Measures of effect size address this issue. The result of each study is 
converted into a common metric which can then be aggregated to determine the. 
degree that an effect is evident in a population (Wolf, 1986). 
It was the seminal work of Glass (1976) that provided a statistical method for 
arriving at a common metric for continuous data (the d-index). This metric, deemed 
the effect size, is derived from each study by dividing the mean difference between 
treated and untreated subjects by the within-group standard deviation. The effect 
sizes are then summed and their average derived. Glass also addressed the call for an 
explicit methodology for the quantitative synthesis of similar, but independent 
studies, and coined the term 'meta-analysis' to describe this process of research 
synthesis. The term is now more commonly applied in the health sciences to the 
statistical method of quantitatively synthesizing the data. Although it is the 
development of effect size analysis that Glass is remembered for, Glass rejects that 
this was his contribution, as others in social sciences, notably Rosenthal (1978), were 
working on effect sizes independently of Glass. He states that it was the 
methodology 'Yhe whole process, fmmjrs t  to hst  that was q contribution" (Hunt, 1997, 
p38). The methodology Glass proposed involved formulating the research problem 
as a question, defining the universe of studies to sample, collecting data from the 
sample of studies, evaluating the quality of the data, synthesizing the data and 
reporting on the synthesis (Glass, 1976). This was "a rigorous altematiwe to the casuai 
narrative dismssions" (ibid., p3) of narrative reviews and was the methodology of the 
first meta-analysis by Smith and Smith (1977), synthesizing psychotherapy outcome 
studies. 
The methodology of research synthesis remained problematic within the social 
sciences, despite Glass's innovation. No widely accepted guidelines on their conduct 
existed. Jackson (1980) randomly sampled 36 reviews from 8 eminent journals within 
sociology, education and psychology in the mid-1970s5 and assessed each against 6 
criteria. He suggested that "reIatiue& Little thought appears t o  have been given to the nzethodr f 
doing integratiue miews" (ibid., p 459) and that reviews were still done less rigorously 
than is possible. Jackson believed that the lack of an explicit methodology for 
integrative reviews signified that social scientists were paying little attention to the 
purpose and role of reviews, and thus were probably not using as powerful methods 
as they could. Furthermore, Jackson opined, the absence of an explicit methodology 
meant that it was difficult to tcain beginning researchers in the performance of 
competent-reviews, that standards for assessing the quality of reviews were non- 
existent and that the accumulation of valid knowledge from previous research was 
consequently hindered. Cooper (1982) provided guidelines that laid out research 
synthesis as a process, similar to that of primary research as previous authors had 
suggested. Cooper also outlined the potential threats to the validity of the research 
synthesis for each step in the process, and perhaps more importantly, suggested how 
reviewers might protect against these threats. 
The Development of Research Synthesis in Health Sciences 
Gerbag and Honvitz (1988) suggested that there have been two methods of research 
synthesis in medicine, in addition to the narrative review: the methodologic analysis 
and the pooled analysis. Both methods have sought to resolve conflicting evidence, 
but in methodologic analysis, each trial is reviewed according to quality standards "to 
judge the scientzzc uaLidity and ckncal @pkcabili'ity fhial resuks" (ibid., p504). Conclusions 
are then drawn from the studies judged methodologically superior and thus are 
qualitative, although a vote counting approach may also be used (see Gifford & 
Feinstein, 1969). In pooled analysis, the data from the clinical trials are combined 
with the goal being to achieve statistical significance when the treatment and control 
groups are compared. Pooled analysis was not new to medicine and reference is 
made earlier in this chapter to Pearson who combined the results of 5 separate 
studies of the correlation between inoculation for typhoid fever and mortality early 
this century (Cooper & Hedges, 1994). The term meta-analysis was quickly adopted 
by the health sciences in the 1980s, by medicine in particular. Sacks, Berrier, Reitman, 
Ancona-Berk and Chalmers (1987) found 13 meta-analyses published in the 1970s, 
S Psychological Bulletin, Annual Review of Psychologr, Review of Educational Research, Annual 
Review of Research in Education, American Sociological Review, Sociological Quarterly, Social 
Problems. 
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and 69 published between 1980 and 1986. Dickersin and Berlin (1992) found 
exponential growth in the publication of meta-analyses6 in the health sciences. 
Computerised searching of MEDLINE~ over the period 1986 to 1991 using the 
subject heading or text word meta-analysis' found growth doubled annually, with 21 
published meta-analyses in 1986 and 431 by 1991. However, the term was not always 
applied with the precision Glass intended. It has been suggested, for instance, that 
Beecher's 1955 exploration of placebo was the first 'meta-analysis' in medicine, 
confusing any quantitative research synthesis with the method of meta-analysis 
(Sacks, et al., 1987; Egger & Davey Smith, 1997). Beecher (1955) randomly identified 
15 observa&onal investigations into the placebo effect in a variety of treatments, 
ranging from headache, cough and sea-sickness to post-operative wound pain. 
Beecher summed the percentages of patients with symptoms satisfactorily relieved by 
placebo for each study and averaged the sum. Beecher did not address an explicit 
study question, define a search strategy, state inclusion or exclusion criteria, or assess 
the studies' methodologic quality; the single characteristic Beecher's review shared 
with the methodology outlined by Glass was the attempt at quantitative summation. 
Beecher's review was certainly a research synthesis, but it had more in common with 
a narrative review than with a meta-analysis and is not justified in being described as 
a meta-analysis. On the other hand, Icylma and Vehvilianen-Julkunen (1997, taking a 
systematic approach to the investigation on the ontology and epistemology of 
research into the concept of hope, termed their qualitative analysis a meta-analysis 
because it was systematic. Gerbag and Horwitz (1988) were just as imprecise and 
termed all the analyses in their review, whether methodologic (qualitative) or pooled 
analyses (quantitative), meta-analyses'. 
The process of research synthesis in the health sciences was not the subject of the 
same discussion that took place in the social sciences during the 1970s, although one 
commentator stated in 1979 
I t  is sun& agnat mtin'sm f[medin'ne] that we have not organised a critical sgmmay, 
by spen'alg or st4bq%cialg, aariapted pen'odicalb, f a l l  releuant randomi~ed controlled 
tn'ah. 
(Cochrane, 1979, p2) 
6 The term meta-analysis is used here in the original sense Glass intended, and does not refer to the 
statistical method of combining studies. 
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When discussion did take place, it tended to focus on statistical methods for 
combining results, rather than the purpose and methodology of research synthesis 
within health sciences. Perhaps for this reason and the rather confused interpretation 
of 'meta-analysis', the quality of meta-analyses conducted in medicine have not been 
high. Sacks, et al. (1987) searched English language medical literature for published 
meta-analyses from 1966 to 1986, finding 86 studies that met their criteria. These 
syntheses were independently assessed by two raters against criteria in six major 
areas: study design, combinability, control of bias, statistical analysis, sensitivity 
analysis and problems of application. Sacks, et al. found that no synthesis received 
more than 14 ratings of adequate out of a total of possible 23; the mean was 7.7 (SD 
2.2). In addition, only 28 percent of the papers addressed issues in all of the six major 
areas. The authors concluded 'hn urgent need exists for iqmued method in literature 
searchin& qualiy evaluation cf triah and ynthesi~ig of the resuLts" (ibid., p450). This 
conclusion was to be supported by Mulrow's (1987) investigation into the quality of 
reviews, published the following month in the Annals of Internal Medicine. 
However, the early critiques on the methodology of reviews in medicine did draw on 
the advances the social sciences had been making in research synthesis. Mulrow's 
criteria for evaluating review articles was drawn from the work of Light and Pillemar 
(1984) and Sacks, et al. (1987) referenced the work of Light and Smith (1971) and 
Glass (1976), although the source of their evaluative criteria was not identified. The 
late 1980s saw increasing attention being given to the methodology of reviews in 
medical literature. This did not just draw attention to meta-analysis, but advanced 
and adapted the methodology of research synthesis. For instance, social sciences tend 
to deal with continuous data, and thus the development of the d-index by Glass 
(1976) to facilitate combination of dissimilar continuous outcomes by conversion to 
a common metric. Quantitative data in medicine, particularly that which is 
meaningful to patients, tends to be dichotomous. The common metric has become a 
ratio of combined results for the treated and untreated groups, using any one of a 
number of statistical methods. Gerbag and Honvitz (1988), following a critique of 7 
pooled analyses and 6 methodologic analyses published between 1969 and 1983, 
believed that the strengths of both methods if combined in a single review, would 
"enhance sn'ent$c ualidip and clinical @pLcabilipn of reviews (ibid., p503). l l i s  echoed a 
critique of meta-analysis conducted in the social sciences by Slavin, who proposed a 
technique he termed 'best-evidence synthesis', which combined the quantification of 
effect sizes and systematic study selection (Slavin, 1986; Slavin, 1995). Slavin 
suggested this approach would address the concerns of rigour that were raised by the 
inclusiveness of early meta-analyses in psychology and education. Gerbag and 
Honvitz (1988) used the noun phrase 'systematic review', in reference to the 
methodologic review section in a meta-analysis, a use that was first indexed in 
MEDLINE~ in 1976. In this review, Shaikh, Vayda and Feldman (1976) had 
methodologically analysed all English language studies evaluating tonsillectomy and 
adenoidectomy identified in a 50-year period, entitling this a systematic review. 
However, this was not the first use of the term; Psyc~itm first indexed the term in a 
study's title in 1936 (Mandel, 1936). The actual origin of the term seems unknown, 
although Gerbag and Horwitz's (1988) suggested combination of the two methods, 
meta-analysis (statistically combining studies using effect size measures) and 
methodological analysis (quality assessment of studies) may be the origin of the 
systematic review in medicine. The term is now understood to mean in health 
sciences, 
the qpLcation ofscieni@c strategies that Lmit bias to the ytematic assembb, ctitica,? 
qtpraisal, and synthesis ofaU ~ h u a n t  stt4dies on a speaic ttopic. 
(Cook, Sackett, & Spitzer, 1995, p167) 
A me&-analysis was defined by the same authors as a systematic review that 
incorporated statistical methods to combine and summarise the results of studies 
(Cook, et al., 1995), although, confusingly, systematic review is also commonly 
applied to reviews that employ the statistical techniques of me&-analysis. Cook, et 
al.'s (1995) definition of meta-analysis, signifying the combined used of systematic 
review and meta-analysis is used throughout the following discussion on conducting 
a me&-analysis. Gerbag and Hotwitz (1988) outlined guidelines for improving the 
rigour of meta-analyses, although these were not very explicit. They recommended 
that meta-analysis incorporate methodologic analysis, explicit criteria for grouping 
and comparison of studies (including the acceptable range of study attributes), and 
the combination of data to provide a quantitative statistic. More explicit guidelines 
have been published since, notably the guidelines for meta-analysis of randomised 
controlled trials from the Potsdam Consultation on Meta-analysis (Cook, et al., 
1995), and the Cochrane Collaboration Handbook (Clarke & Oxman, 1999). 
The Cochrane Collaboration, established in 1992, was a response to the growing 
need within healthcare for summative information on effective interventions. It is an 
international organisation that aims to prepare and maintain meta-analyses of the 
effectiveness of health interventions. The Collaboration is named after Archie 
Cochrane, an epidemiologist who recognised that information from randomised 
controlled trials needed to be collected into reviews that were methodologically 
rigorous (Cochrane, 1972). To date 663 meta-analyses have been completed with a 
further 624 protocols registered. 
Conducting a Meta-analysis 
Meta-analyses are observational investigations where the unit of analysis is not 
individual outcomes, but the results of the original studies. As such, meta-analyses 
can be likened to "an @idemiology fnsuZtsJ' (Jenick, 1989, p39). However, meta-analysis 
is potentially subject to the same biases that affect all observational studies. For a 
meta-analysis to be reliable and valid, it must rely upon the quality of the included 
studies and, as importantly, the methodology of the meta-analysis itself (Cook, et al., 
1995). The Potsdam Consultation on Meta-analysis sought to improve the conduct 
of meta-analyses within the constraints of "the naZ world 6 i@elfed stud;es" (ibid., 
p167). The participants identified the need to describe and disseminate good review 
practice and aimed to do this through the production of guidelines on the conduct of 
meta-analyses of randomised controlled trials. These guidelines were published by 
Cook, et al. (1995) and, along with the NHS Centre for Review and Dissemination's 
(1996) guides for systematic review and the Cochrane Handbook (Clarke & Oxman, 
1999), are used to inform the following discussion. As befits the conduct of any 
research, the three guidelines recommend that a protocol be developed for the meta- 
analysis and this should pose a research question specifying the study population, 
intervention and outcomes. The protocol should also specify the methods used to 
search for all potentially relevant data, the selection criteria, the methodological 
assessment of quality and the methods used to analyse the data. The protocol should 
also specify any sub-group hypothesis testing apriori. 
Search Strategy and S tu4  Selection 
The meta-analysis when reported should specify the strategy used to identify studies 
for review. This should outline the databases used, other sources of studies, language 
restrictions and attempts to identify unpublished studies. It has been suggested that 
there is a bias on publication towards studies that have a positive effect over those 
that report no effect (Rennie & Flanagin, 1992), and that English language reports 
tend to favour positive reports (Egger, Zellweger-Zahner, Schneider, Junker, 
Lengeler & Antes, 1997). Scherer, Dickersin, and Langenberg (1994) suggested that 
up to 50 percent of studies do not reach publication in journals. Although inclusion 
of unpublished studies is contentious (Cook, et al., 1993), reliance on published 
studies and, or, only those published in English may over-estimate the effect of a 
treatment (Eger & Davey Smith, 1995). The publication of the search strategy 
allows readers of reviews to assess the efforts of the authors of the meta-analysis 
have made to overcome publication and language bias. 
Repoas of meta-analyses should identify the selection criteria for inclusion and 
exclusion of studies that address the research question. These criteria should be 
based upon the population, intervention(s), outcomes and study design specified in 
the protocol. Reasons for exclusion should be presented, allowing the reader to 
assess the reproducibility of the study selection. The process of selection should be 
conducted by at least two reviewers in order to minimise selection bias, with a 
process for arbitration of disagreements between the reviewers. Once the included 
studies have been selected, a methodologic assessment of the studies' quality should 
be conducted. Moher, Pham, Jones, Cook, Jadad, Tugwell and Klassen (1998), in a 
re-analysis of 11 randomly selected meta-analyses involving 127 RCTs, found that 
unblinded trials were associated with an increased estimate of benefit of 34 percent 
when compared with blinded trials. A similar over-estimate of benefit (37 percent) 
was produced when trials employing random allocation were compared with those 
that did not. However, it is important that the quality assessment not confuse 
methodologic quality with quality of reporting. For this reason, quality assessment 
should be limited to assessing procedures for minimising threats to internal validity 
e.g. method of allocation and concealment, blinding, objective criteria for outcomes, 
completeness of follow-up and handling of departures from the original protocol. 
Moher, Jadad, Nichol, Penman, Tugwell and Walsh (1995) identified 25 scales and 9 
checklists to assess the 'quality' of studies based on generally accepted criteria. Only 
one tool had been validated Oadad, 1998). If a tool is used, the scoring system should 
be transparent. However, the Cochrane Collaboration does not recommend the use 
of quality scoring systems (Clarke & Oxman, 1999). The quality assessment provides 
information that may explain heterogeneity or be used for the conduct of sensitivity 
analysis. 
Data Extraction and Syntharis 
The data extraction and synthetic phase of a meta-analysis should be explicit, 
reproducible and minimise bias. To this end the data extraction should be conducted 
by independent reviewers with a standardised coding form and methods for 
resolution of disagreements between the reviewers should be reported (NHS Cenn-e 
for Reviews and Dissemination, 1996). It is also recommended that, where there are 
ambiguities in the published studies, the original investigators be contacted for 
clarification. When the data is sparse, of low quality or too heterogenous to proceed 
with a statistical aggregation, the reviewers should perform a narrative analysis. 
Where statistical aggregation is possible, all the relevant and clinically useful measures 
should be used. The goal of effect size measures is to obtain a number free of the 
original unit of measure in order to index 'the degee afd@arttlefmm the null hypothesis a f  
the alternative hypathesis" (Cohen, 1977, p20). Two measures of effect size are generally 
utilised for categorical or binary data, where one outcome is preferred and the other 
is in some sense undesirable. These are the odds ratio (also known as the cross- 
product ratio and abbreviated to OR) and the relative risk (also known as the rate 
ratio and abbreviated to RR). The relative risk is the ratio of two probabilities and is 
calculated from Xl/X2, where X, and X, are the average effect for the two 
comparison groups. The odds ratio is the ratio of odds estimable for the outcome in 
each group, and is calculated from (TI1/1T,)/(II3/n4), where and IT, are the 
numbers with the outcome of interest in the two groups and and n, are the 
numbers without the outcome of interest in the two groups. 
The odds ratio is the measure most commonly used in health-related meta-analysis 
primarily because it is estimable from a variety of study designs. It  also has statistical 
properties of practical importance; for instance it can assume any value between 0 
and m, no matter what the value of the two probabilities beiig compared. 
Additionally, when the proportions being compared are small, the odds ratio 
approximates the relative risk (Cooper & Hedges, 1994). This feature makes the odds 
ratio acceptable in studies where the event rate is low, as in large pharmaceutical mals 
examining differences in mortality when two therapies are being compared. 
However, in trials where the event rate is high, the odds ratio can considerably 
overestimate the relative risk, potentially leading to precipitate conclusions regarding 
the effectiveness of a therapy. Trials investigating the effectiveness of therapies in 
ulcer healing are an example of the latter, as healing is a relatively common event. 
Unfortunately, if the chances are high that a participant will experience the outcome 
under study, many values for the relative risk are mathematically impossible. For 
instance if the mean event rate in one group is 0.4 (or 40 percent), only values for the 
interval 0 I RR I 2.5 are possible. Tests for between-study homogeneity can 
consequently over-estimate heterogeneity7 as a result of variation in relative risk, 
leading to a conclusion of significant heterogeneity where heterogeneity is not 
significant. This constraint does not characterise the odds ratio (Cooper & Hedges, 
1994). 
It  is reasonable to combine studies that are conducted on similar populations with 
similar study designs, entry criteria and treatment protocols. Such groups of studies 
are rare, however. More commonly, studies use different entry criteria, definitions of 
disease, methods of measuring the outcome and variations in treatment pickersin & 
Berlin, 1992). Groups of studies that vary in design, population and protocols are 
likely to produce variance in the estimation of the treatment effect. The issue is 
whether the variation (or heterogeneity) in study results is greater than is compatible 
with the play of chance phompson, 1994). An assumption underpinning pooling of 
effects is that each study provides an estimate of effect size that is representative of 
the population effect size (Wolf, 1986; Bailey, 1987). This assumption and the 
generalisation of a pooled statistic to a population of future patients have been 
described as a leap of faith phompson & Pocock, 1991). Combining studies and 
generalising the pooled statistic may be appropriate if a series of studies provide a 
homogenous estimate of the effect size, suggesting the studies are testing the same 
hypothesis. However, 
$these studies are hetemgeneota, then the question of whether each stu4 zs testing the 
same h$othesis arises. Hetemgeneigprovides a niarnif'g that it rnq not be appmpriate 
to combine and syntheske all the stu4 restdts in a rneta-ana~s~s 
(Wolf, 1986, p42) 
7 Statistical heterogeneity is variation in study results, which may be caused by clinical or 
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Heterogeneity of studies is substantial when between study estimates of treatment 
effect vary above that expected by sampling error or chance (Dickersin & Berlin, 
1992; Thompson, 1994; Sutton, Jones, Abrams, et al., 1999). When the studies differ 
substantially, the pooled effect size may not be representative of the components 
making up the average (Dickersin & Berlin, 1992). Heterogeneity usually tests the 
null hypothesis, that there is no significant heterogeneity among the study results, 
using chi-square statistics. A chi-square statistic has on average a value equal to its 
degrees of freedom (Tnompson & Pocock, 1991). The criteria for rejecting the null 
hypothesis is the subject of debate, but it has been recommended that a less stringent 
than normal criteria apply as the power of the chi-square to detect heterogeneity is 
not strong (Fleiss, 1986; Bailey, 1987). A significance threshold of p50.10 is the 
conventional criteria for rejecting the null hypothesis when testing heterogeneity 
(Bailey, 1987). However, it should be noted that a n  insignificant test result couldn't 
be interpreted as evidence of homogeneity, as the low power of the test may not 
detect even moderate heterogeneity. 
The decision to pool treatment effects should not rest on the results of a statistical 
test alone, although Thompson and Pocock (1991, p1352) notes an investigator 
should feel '%@pier to ignore pmblems o f  cdnical hetemgeneig direct evidence o f  statistical 
hetemgeneip is lacking". The guiding principle should be to investigate the impact of 
clinical and methodological differences, rather than rely on statistical testing alone 
(Bailey, 1987; Thompson & Pocock, 1991). This can be achieved by the use of 
sensitivity analyses (removing specific studies meeting set criteria and exploring the 
impact of this on the pooled effect size). Sensitivity analyses test the robustness of 
results relative to key assumptions and decisions made about the data. Generally, 
sensitivity testing is conducted where there may be any ambiguity about the trials' 
methodology, uncertainty about whether the trials meet inclusion and exclusion 
criteria, test missing data and determine the vulnerability of the results to small shifts 
in the number of events between the treatment and control groups. 
If all studies were similar in design, they would differ "on4 Cy oirtue fhaoing w e d j t ~ s t  a
sa@b fobseruationsfmm the totalpopulation" (Thompson & Pocock, 1991 p262) and the 
effect sizes would differ from that of the true population only because of sampling 
methodological differences in trials (T'hompson, 1994). 
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error (also known as conditional variance). However, it is rarely the case that studies 
are perfect replicas of each other. Most often studies differ methodologically. What is 
at issue is described as one of the most subtle and difficult problems in research 
synthesis; the specification of the universeB to which the researcher wishes to 
generalise, which in turn determines how the results of the synthesis are interpreted 
(Cooper & Hedges, 1994). 
Two models for combining effect sizes have been advanced: the fxed effects model 
and the random effects model. Essentially the two models are distinguished by how 
the definition of the universe of studies to which the sample of studies is 
generalisable. A fxed effects model assumes that 
The universe to which generhqations are made consists of ensembles of studies identical 
to those in the study sample exCept3r theparticuhrpeopr'e (orprimay saqhng unzts) 
that appear m the studies. 
(Cooper &Hedges, 1994 p30). 
A random effects model assumes the studies are drawn from a sample of a collection 
or population of studies. The universe to which generalisations are made is the 
population of studies from which the sample is drawn, rather than all hypothetically 
possible studies. The studies in this universe differ from the sample studies along two 
dimensions: study characteristics and effect size, and the sampling of people into the 
individual studies, resulting in variations in the observed effect sizes. Cooper and 
Hedges (1994, p31) note that 
The generalization is not [sic], as it was in thefixed efects case, t o  a universe 
consisting of ensembles of studies with comsponding members ofthe ensembles having 
identicaI characteristics and effect size parpaeters. Instead the studies in the study 
sample (and their effect si~parameters) dyer fmm those in the universe by as much 
as might be expected as a consequence ofdmwing a sa@lefmm apopulation. 
The question of whether to use a fxed or random effects model in combining effect 
sizes must be made on the degree to which the studies are similar. Consideration 
8 The universe is the hypothetical collection of studies that could be conducted and about mhich the 
synthesis will generalise. The study sample is the collection of studies that have been assembled for 
use in the systematic revlem. 
should be given to the features of the participants and to the studies' methodologies, 
as well as a statistical measure of heterogeneity. 
The synthesis of perfectly alike studies might use a simple fixed effects model, with 
the estimation of population effect size being derived from the average of the 
observed studies' effect sizes. A simple fxed effects model would give each study the 
same weight within a synthesis. However, if studies vary by sample size, smaller 
studies would have the same weighting as larger samples, despite studies with larger 
samples being acknowledged as being more precise in determining a treatment effect 
(Cooper & Hedges, 1994). A more complex fmed effects model assumes the 
ensemble of studies is generalisable to the hypothetical universe of studies, but 
weights the studies on the basis of their relative sample sizes, with more weight being 
given to studies with larger samples. Weighting is also used in the random effects 
model, although the smaller studies are given greater weights than in the fixed effects 
model. This acknowledges that the results of smaller studies represent random 
variation within the universe of studies, rather than lower precision. The random 
effects model provides more conservative estimates of the "szgn$cance of the auemge 
effect sites over studies in  thepresence ofunescpkined heterogenei'" (Cooper & Hedges, 1994, 
p275) than the fxed effects model. It  is for this reason the Cochrane Collaboration 
recommends that the decision regarding which model for combination of effect sizes 
is to he used should be made prior to the combination of studies (Oxman, Cook, & 
Guyatt, 1994), thus avoiding the temptation to present the findings using the more 
favourable model. 
Interpretation and Presentation $Resulii 
The reporting of results should include evidence tables that specify the design, 
sample size, treatment effect, outcome measures and information likely to have an 
impact on the internal validity of the study.' The summary data should be shown 
graphically as well as reported in the text, and clinically relevant measures of 
effectiveness, such as 'number needed to treat' should be stated." The results should 
also report confidence intervals at a specified level of probability. Consideration 
Method of allocation, allocation concealment, blinding, completeness of follow-up and treatment of 
mithdrawals. 
'0 Number needed to treat (NN'I) to cause one more benefiud event in the treatment than in the 
control group. It is calculated by determining the inverse of the absolute difference betmecn the 
treahnent and control groups. 
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should be given to publication bias when examining the results. A funnel plot plots 
the precision of each study against effect size. Where publication bias is absent, the 
expectation is that the plot should represent an inverse funnel with the more precise 
studies at the peak and less precise studies at the base of the funnel. An asymmetrical 
funnel plot suggests the presence of publication bias. However, it may also suggest 
bias due to the usually poorer methodological quality of small studies, and for this 
reason a funnel plot should only be used to draw attention to a potential problem. 
The power of this method is at its most limited when a review consists of a few small 
studies; for this reason it is not part of the publication of a Cochrane meta-analysis 
(Clarke & Oxman, 1999). 
When interpreting the results, the reviewers must be mindful of the needs of clinical 
practice and thus must situate the interpretation within current healthcare practices. 
It would be of little use to practitioners to report results of outmoded practices, 
unless this was to confirm they are ineffective. The interpretation should call upon 
other available evidence to better make sense of the inferences about the direction of 
effect; human physiological data and observational data may support the likelihood 
of a causal relationship. The interpretation should also consider dose-dependent 
responses where relevant, and adverse effects associated with the treatment. When 
considering the strength of inferences about the effectiveness of an intervention, the 
report should also consider the methodologic limitations of the included studies and 
the meta-analysis. The report should consider the implications of the meta-analysis 
for clinical practice, although these implications should be limited to those that can 
be clearly derived from the evidence, and should not be diretive of practice. Finally 
the report should propose a future research agenda that addresses both clinical and 
methodologic issues. 
Conclusion 
Research synthesis serves a variety of purposes; in the increasingly complex world of 
healthcare interventions, the primary purpose of research synthesis is to advance 
knowledge through the accumulation of all studies relevant to a specific question, in 
order to test a hypothesis or generate .an answer to the question. Advances in 
research synthesis are owed to developments in the social sciences during the 1970s 
and early 1980s. The health sciences, and medicine in particular, have drawn on these 
developments, as it became apparent just how vulnerable narrative reviews were to 
bias. The nexus of this vulnerability and the need to ensure clinical practice is 
effective has ensured the place of research synthesis as a legitimate research activity. 
The Cochrane Collaboration, with its clear guidelines for methodologic analysis and 
quantitative pooling, through meta-analysis, have provided a home for the output of 
this research actimty in health, as well as a methodologic sanctuary for the science of 
meta-analysis. 
Chapter 3. METHOD 
This meta-analysis was conducted as part of a larger review, for use in an explicit 
evidence-based clinical practice guideline on the care of patients with chronic leg 
ulcers. It  represents an aprion' specified subgroup analysis to investigate the question 
Is pentox&Iline and covqression more effective in healing venous I g  uIcelcen than 
coqbression andphcebo? 
The principal reviewer (Andrew Jull; AJ) was assisted in the larger review by two 
other reviewers, Associate Professor Bruce Arroll (BA), University of Auckland and 
Dr Jill Waters UW), Auckland Healthcare Services Ltd. The roles of the principal 
reviewer and co-reviewers are indicated throughout this chapter by use of their 
respective initials where the tasks were shared (See A p p e n d x  7). Where no co-reviewer 
is indicated, the principal reviewer was solely responsible for the task. 
Search Strategy 
The CENTRAL registers of the Cochrane Wounds Group and the Cochrane 
Peripheral Vascular Diseases Group were searched for randomised controlled trials 
and controlled clinical trials of pentoxifylline in the treatment of venous leg ulcers. In 
addition, the manufacturer of pentoxifylline (Hoechst) was contacted via the New 
Zealand distributor for details of any unpublished or ongoing studies. Articles 
reviewing the use of pentoxifylline in the treatment of ulceration were obtained and 
citations within these reviews and the primary studies were scrutinised to identify any 
additional studies. 
The two Collaborative Review Groups (CRG) liaise to avoid duplication of searches. 
The Wounds CRG is responsible for reviewing interventions for venous ulceration. 
The Peripheral Vascular Diseases CRG is responsible for reviewing interventions for 
arterial and mixed arterial/venous leg ulceration. The CENTRAL registers contain 
references from comprehensive searches of electronic databases, handsearches of 
relevant journals and conference proceedings, and contacts with product companies 
and experts in the field. In addition the citations of obtained papers are scrutinised by 
the CRGs for additional studies. The search strategy for each respective CRG is 
published on the Cochrane Library and has been reproduced in Appendices 2 and 3. 
Criteria for Inclusion of Studies 
Types ofpartinjhznts: Studies which involved adult participants of any age and in any 
care setting, described as having 'venous leg ulcers' or equivalent (stasis ulcers, 
gravitational ulcers, varicose ulcers or post-thrombotic ulcers) were included. The 
criterion for diagnosis of venous ulceration was identified where available, but the 
lack of internationally agreed diagnostic criteria meant that this could not be used as 
an inclusion or exclusion criterion. Studies which described inclusion of participants 
with venous ulceratior~ have implicit a clinical assessment of aetiology and were 
included in the review unless other criteria led to their exclusion. Sensitivity analyses 
were conducted to determine the impact of trials that relied on clinical assessment 
alone without further non-invasive testing (such as Doppler ultrasonography) to 
determine aetiology. Trials that recruited participants with other causes of ulceration, 
such as arterial, diabetic or rheumatoid ulceration, were included only if the results of 
those participants with venous ulceration were presented separately. 
Types ofintervention: Only trials that compared pentoxifylline and compression therapy 
with a placebo and compression therapy in the treatment of chronic venous 
ulceration were included. 
Types of outcome measures: The outcome measures must have been objectively 
measured. The primary outcome measures for this investigation were measures that 
could be dichotomised, such as time to complete healing, proportion of ulcers healed 
within the trial period, or rate of change in ulcer area within the trial period. The 
outcome of healing must have been operationally defmed as 100% complete re- 
epithelialisation of the ulcer or specified as complete healing. 
Types $studies: Trials were only included if the allocation of participants to therapies 
was described as 'randomised' or an actual random allocation schedule was 
described. Studies that employed pseudo-randomisation techniques, such as 
allocation by birth date, patient number or alternate weeks, would not have been 
included, but no studies described using such strategies. 
Initial Selection of Studies 
The results of the searches of the CENTRAL register for each group were forwarded 
to the prinicipal reviewer in text file formats via email. The manufacturer of 
pentoxifylline (Hoechst) also forwarded a list of studies, although no studies not 
previously identified by the Cochrane groups were identified by this means. Print 
copies of each text file were examined by the author and a CO-reviewer (BA) for 
relevant studies. These lists were compared and agreement was reached regarding 
studies identified as candidates for further examination. These studies were extracted. 
electronically from the various text files and compiled into a single 'final list' text file. 
All studies on this list were obtai~ed for further examination. Review articles were 
also extracted from the list, obtained and scrutinised for studies relevant to the 
investigation. 
Translation of Studies 
Translations of the methods, results and any tables, figures and graphs were obtained 
for three articles (Schiirmann & Eberhardt, 1986; Apollonio & Angeletti, 1992; 
Herdy, Thomaz, Souza, Robadey & Rodolfo 1997). The iranslation of Schurmann 
and Eberhardt (1986) was obtained through the Cochrane Collaboration Sub-fertility 
and Dysmenorrhoea Review Group. Dr. Jorg Neumann translated the methods and 
results sections, and captions to the graphs from the original German. The 
translations of Apollonio and Angeletti (1992) and Herdy, et al. (1997) were funded 
by the New Zealand Centre for Evidence Based Nursing, and commercial translators 
provided the translation from Italian (European Translation Services) and Portuguese 
(Language Links Ltd). 
Selection of Included Studies 
The principal reviewer (An and a CO-reviewer (BA) each independently reviewed the 
ten studies obtained from the final list of the initial selection, studies identified from 
review articles and studies identified from citations of obtained studies. Each study 
was coded using the Inclusion/Exclusion Criteria Coding Sheet (See Appendix 4) and 
an opinion was formed by each reviewer as to whether the studies met the inclusion 
criteria. The two reviewers met to discuss the inclusion or exclusion of each study. A 
study was only included if both reviewers were in agreement that it met the inclusion 
criteria. Where disagreement existed, it was resolved by the decision of the third 
reviewer (JW), or the advice of the Cochrane Wound Review Group. 
Data Extraction 
Data was extracted from the included studies by the principal reviewer using a coding 
form (See Appendx 4). 'Che coding form was constructed drawing on the protocol 
guiding the meta-analysis and data extraction forms usedpreviously by the Cochrane 
Wounds CRG. The principal reviewer (An piloted the coding form in order to 
determine the adequacy and accuracy of data extraction, and adjusted the coding 
form as appropriate. The coding form for each included study was scrutinised by a 
second reviewer UW] to ensure accuracy and completeness of data collection. 
Disagreements were either resolved in discussion, or by the arbitration of another co- 
reviewer (BA). The decision concerning the comparisons to be made was the result 
of a discussion between. the principal reviewer and the CO-reviewers. 
Data Synthesis 
In order to determine what model should be used to combine the studies, they were 
examined for methodological and clinical heterogeneity. All studies were randomised 
controlled trials, used blinding and compared the treatment to a matching placebo. 
Similarly, all trials attempted to include only patients with venous insufficiency, 
although the exact method by which the diagnosis was determined varied. 
Schiirmann and Eberhardt (1986) did not specify how the diagnosis of venous 
insufficiency was determined, although the title of the study indicated only people 
with varicose or post-thrombotic ulcers were included. However, there was an 
overlap in the methods used by the other studies, with objective assessments utilised 
as well as clinical history in all studies (Tabh 3, seepage 38). With the exception of 
Dale, Ruckley, Harper, Gibson, Nelson and Prescott (1999), who reported the 
median Ankle Brachial Index (ABI), and Schiirmann and Eberhardt (1986), who did 
not report the mean or median Ankle Brachial Index for their participants, the 
participants in the other trials (Colgan, Dormandy, Jones, Schraibman, Shanik, & 
Young, 1990; Barbarino, 1992; Falanga, Fujitani, Diaz, Hunter, Jorizzo, Lawrence, 
Lee, Menzoian, Tretbar, Holloway, Hoballall, Seabrook, McMillan, 8: Wolf, 1999) all 
had a mean AB1 greater than 0.8, indicating the absence of significant arterial 
insufficiency (Stoffers, ICester, IGser, Rinkens, Kitslaar & Knotterus, 1996). The 
mean AB1 (control: treatment) for the three studies was 0.85:0.84, 1.06:1.05, and 
1.1:l.l respectively. 
The populations included in each study were also examined for variation that might 
influence the outcome of data synthesis. Schurmann and Eberhardt (1986) provided 
no demographic data, apart from mean ulcer size, although the authors stated age, 
height, weight and history of ulceration were comparable. Age, sex ratio 
(male:female), mean ulcer size and mean ulcer duration were the population 
characteristics examined (Tables 4 and 5, see page 39). The within-study mean. ages 
(control: treatment) were similar in all other mals as was the between-study variation, 
with the studies reflecting the association between ageing and prevalence of venous 
ulceration (Baker, et al., 1991). The within-study ratio of male to female participants 
l I I I l 
Table 4: Characteristics of popuhtions of included studies - Mean a2e and sex ratio. 
Barbmino (1992) 
Schiirmann 1986 
Barbarino 1992 
Dale 1999 
Falan 1999 60.4 
appears to vary, although each study has reported non-significant variation. On the 
whole, there were greater numbers of female participants, reflecting the greater 
incidence of venous ulceration in women in prevalence studies (Nelzin, Bergqvist, & 
Lindhagen, 1994). The exception to this is Falanga, et al. (1999), who reported a 
greater number of male than female participants were included in their trial. This may 
reflect a sub-population that varies from that of European studies and could be cause 
Dale (1999) 1 r/ I J I r' I 1 
J J J J 
for caution in determining the statistical model with which to combine the studies. 
However, it is worth noting that Falanga, et al. had a similar relative risk to Dale, et 
al. (1999), 1.18 compared to 1.23, despite Dale, et al. having a greater ratio of female 
participants. This suggests that the sex ratio may have little systematic impact on the 
trials' outcomes. 
The within-study variations for mean ulcer size were similar (0.4cm2-3.1cm2). There 
was between-study variation, with the range for controls being 4.7cm2-14.5cm2, and 
2.5cm2-14.1cm2 for the treatment groups. The exception was Schurmann and 
Eberhardt (1986), who reported a within-in study mean ulcer size that favoured the 
treatment group. The between-study variation seems likely to have had little 
systematic impact on studies' results as the relative risk for the two studies of similar 
size (Colgan, et al., 1990; Falanga, et al., 1999) was 2.12 and 1.18 respectively. This 
was despite one having the smaller mean ulcer sizes and the other considerably larger 
mean ulcer sizes. However, this may be further cause for caution in combining the 
Table 5: Characteristics ofpupulations ofincluded studies - Mean ulcersz~e and dumtiun. +Dale, 
et a,! 0999) &orted the median mm'mum ulcer diameter. which lyas 2.9cm lcontmN and 2.7m 
studies. The mean ulcer duration was reported in three studies (Barbarino, 1992; 
Colgan, et al., 1990; Falanga, et al., 1999), whilst Dale, et al. (1999) reported the 
median ulcer duration. If the sample dismbution is not skewed, the median should 
closely approximate the mean. The mean was similar in all cases, with exception of 
Barbarino (1992). The participants in this study had a considerably longer history of 
ulceration. This reflects the inclusion criteria (ulcers of greater than 2 years duration), 
and the study's aim to investigate refractory ulcers. This may be further reason for 
caution when combining the studies. 
Schurmam (1986) 
Colgan (1990) 
Barbadno (1992) 
Dale (1999)t 
Falanm (1999) 
In summary, the trial metl~odologies, as far as can be determined, were substantially 
similar, as were the characteristics of the studies' samples. However, some 
differences in the samples and the study methods suggested caution be adopted in 
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combining the studies. Therefore, the studies were combined using a fixed effects 
model and the robustness of the pooled result was tested by combining the studies 
using a random effects model. Sensitivity analyses were also performed, to examine 
the impact of clinical heterogeneity. The data was synthesised by the principal 
reviewer using RevMan Version 4.03 (Cochrane Collaboration, 1999). RevMan is 
public domain computer software available over the Intemet from Cochrane file 
transfer sites (www.cochrane.org-.uk). It was developed by the Cochrane 
Collaboration to support the performance of meta-analyses and contains word 
processing, statistical and reference management components. The statistical analysis 
and Peto tables for this investigation were performed by the principal reviewer using 
RevMan. The Peto tables were exported into Microsoft Word as bitmaps using 
Microsoft Paint. The variation in event rates (the control group event rates varied 
from 16 percent to greater than 50 percent) was likely to introduce an over-. 
estimation of heterogeneity, if relative risk was used as the summary statistic.' 
However, relative risk was used to report results in the knowledge that it more 
accurately represents risk differences when study event rates are high, and that an 
insignificant test for heterogeneity will represent greater between-study homogeneity 
than the test result actually suggests when relative risk is used. 
l See page 28 for a discussion of heterogeneity and relative risk. 
Chapter 4. DATA COLLECTION & SYNTHESIS 
Ten separate studies concerning venous ulcers and pentoxifylline were selected from 
the studies retrieved from the central registers of the Cochrane Peripheral Vascular 
Diseases and Wound Review Groups as deserving further investigation. No new 
studies were identified from the lists provided by the manufacturer of pentoxifylline 
(Hoechst). One further study was identified after the search had been completed 
(Falanga, et al., 1999). The unpublished trial from 1997 was referenced in a review 
article (Falanga, 1999) brought to the attention of the principal reviewer by the 
Cochrane Wounds Group. The trial's authors were contacted for data from the 
study; in actuality, the trial had just been published, but was not yet referenced oil the 
electronic databases, or available in. Australasian libraries. An imprint of the article 
was faxed by the authors to the principal reviewer. 
Ten of the eleven studies were described as randomised controlled trials; one study 
(Angelides & Weil von der Ahe, 1989) did not have a control group and was not 
assessed further. Five studies (Apollonio & Angelem, 1992; Arenas & Atoche, 1988; 
Herdy et al, 1997; Mirshahi, et al., 1995; Weitgasser, 1983) did not meet the criteria 
for inclusion in this meta-analysis. Reasons for exclusion included: subjective 
outcome assessments, compression therapy not being used, physiological outconles 
reported, and the comparison group not being a placebo (or no therapy). The 
excluded studies and the reason for each study's exclusion are detailed below. 
Details of excluded studies 
Weitgaser (1983): Double-blind randomised controlled trial; allocation concealment 
not described; participants received pentoxifylline 1200mg daily or placebo; 60 
participants, 30 in each arm; participants received treatment for minimum of 6 weeks 
and maximum of 8 weeks; outcome healing - assessed as good (complete closure or 
considerable reduction in ulcer size and reduction in symptoms), satisfactory (gradual 
healing marked by islands of granulation tissue and marginal epithelialisation, and 
reduction in symptoms), no change, or worse; outcome favoured treatment (good 
response 20130 versus 7/30 in placebo). Reason for exclusion: outcome 
assessment subjective; compression therapy not used. 
Arenas and Atocbe (1988): Double-blind randomised controlled trial; allocation 
concealment not described; participants received pentoxifylline 1200mg daily or 
placebo; 30 participants, 18 in treatment arm and 12 in the control arm; withdrawals 
excluded from analysis (3 in treatment arm, 2 in control arm); duration of treatment 
not described; participants followed up fbr 6 months; outcome healing - assessed as 
healed (95-100% improvement), significant improvement (60.94% improvement), 
improvement (30-59% improvement), no change, or worse; healing and significant 
improvement favoiired the treatment arm (58.4% versus 30%): Reason for 
exclusion: outcome assessment subjective; conlpression therapy not used. . 
Apollonio and Angeletti (1992): randomised controlled trial; allocation concealment not 
described; treatment blinding not described; participmts received standardised 
treatment (compression bandaging and topical therapy) in addition to pentoxfiiline 
1200mg daily or defibrotide 800mg daily; 23 participants (25 lesions), 12 in 
defibrotide a m  and 11 in the pentoxifylline arm; duration of treaAment not reported: 
participants followed up for 6 months; outcome healing - favoureddefibrotide arm 
at 12 weeks (12/13 versus 10/12 ulcers healed), all ulcers healed in both groups at 24 
weeks. Reason for exclusion: comparison group not a placebo. 
Minhabi, et  al; (1995): Double-blind randomised controlled trial; allocation 
concealment not described; participants received pentoxifylline 1200mg daily or 
placebo; 10 participants 4 participants in treatment arm and 6 participants in the 
control arm; participants received treatment for 2 months; punch biopsies taken 
from the centre of each ulcer prior to treatment and at 2 months; outcome - fibrin 
and elastase reduced in treatment arm. Reason for exclusion: outcome not 
meaningful to patients; physiological assay of effectiveness of pentoxifylline in 
reducing fibrin production. 
Her4, e t  al. (1997): Randomised controlled trial; allocation concealment not 
described; treatment blinding not described; participants received standardised 
therapy (leg elevation, dietary advice, daily dressing with saline, povidine-iodine and 
liquid paraffin) in addition to pentoxifylline 1200mg daily or placebo; 12 participants, 
6 in each arm; no withdrawals; participants received therapy for 12 weeks; mean ulcer 
size favoured control at baseline (9.53cm2 versus 6.0cm3; outcome healing - no 
ulcers completely healed at trial's conclusion, mean reduction in ulcer size favoured 
treatment arm (2.21cmZ versus 0.62cm2). Reason for exclusion: compression 
therapy not used. 
Description of included studies 
Detailed tables of the characteristics of included studies are reported in Appendix 6. 
Five studies (Barbarino, 1992; Colgan, et al., 1990; Dale, et al., 1999; Falanga, et al, 
1999; Schiimann & Eberhardt, 1986) met the criteria for inclusion in this meta- 
analysis. Details regarding one trial (Dale, et al., 1999) have been extracted from an 
additional report Prescott, Nelson, Dale, Harper & Ruckley, 1998). The numbers of 
participants included in the trials ranged h-om 3.2 to 200. Three trials were 2 arm 
parallel group trials (Barbarino, 1992; Colgan, et al., 1990; Schiirmann & Eberhardt, 
1886). A fourth trial was a stratified factorial trial wit11 three strata, one of which only 
iriclllded participants with a pure venous aetiology (Dale, et al., 1999). Within the 
venous .strata, three treatments @entoxifyll'ie versus a placebo, four layer 
compression bandaging versus single layer bandaging, hydrocolioid dressing versus a 
knitted viscose dressing) were tested, randomly allocated between 2 parallel groups 
(see F&un 3). The fifth trial was a three arm parallel group trial comparing 1200mg 
and 2400mg doses of pentoxifylline with a placebo (Falanga, et al., 1999). 
All participants in the trials were deemed to have venous ulceration and, with the 
exception of Schiirmann and Eberhardt (1986), all trials reported how this 
determination was made. The methods of diagnosis were generally similar. Colgan, et 
al. (1990) relied upon clinical appearance and exclusion of significant arterial 
insufficiency by calculation of the ankle-brachial index (ABI), which is also known as 
the ankle-arm index or ratio, the Winsor Index, and the ankle-brachial pressure 
index. This is a ratio of systolic blood pressure measured at the ankle divided by the 
systolic blood pressure measured at the upper arm. A ratio of greater than 1.0 is 
considered indicative of an absence of arterial pathology. There is general agreement 
that a ratio of less than 0.8 to 0.9 indicates arterial insufficiency, although there has 
been only one well conducted diagnostic study within a general practice setting to 
test this (Stoffers, et al., 1996). Barbarino (1992) relied on diagnosis by calculation of 
the ABI, determination of venous pressure at the ankle, valvular incompetence and 
the presence of venous reflux, all using Doppler ultrasound. Dale, et al. (1999) used 
clinical assessment, calculation of AB1 and Doppler demonstration of venous 
pathology (sapheno-femoral and, or sapheno-popliteal reflux) in the same leg as the 
ulceration (Prescotf et al., 1998). Falanga, et al. (1999) relied upon clinical assessment 
(presence of hyperpigmentation, lipodematosclerosis, varicose veins and medial 
location of the ulcer) and the presence of venous reflux as determined by continuous 
wave Doppler ultrasound. As indicated earlier Schiirmann and Eberhardt (1986) did 
not report how their participants were determined to have venous ulceration, 
although some determination is implicit in the trial's title, as it referred to participants 
having varicose or post-thrombotic ulcers. 
Venous 
aetiologg 
1 
Four trials varied in the type of compression bandaging systems used. Schiirmann 
and Eberhardt (1986) did not report the type of compression used. Both Colgan, et 
al. (1990) and Barbarino (1992) described the use of a two layer bandaging system, 
although the type of two layer system (or the brand) is not described. Colgan, et al. 
(1990) state that the application technique was standardised, but do not report how 
this was determined. Dale, et al. (1999) used two different bandaging systems 
balanced between the two arms: 97 participants used a four layer elastic bandage and 
the other 103 used a single layer inelastic system. Falanga, et al. (1999) used Unna 
boot to achieve compression; this consists of a zinc-impregnated bandage and a 
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short-stretch elastic bandage. Standardisation of application of compression was not 
reported in either of these two trials. One trial indicated the dressings and bandages 
were changed at least weekly or as required (Dale, et al., 1999). None of the other 
four studies indicated the frequency at which dressings or bandages were changed. 
Three trials (Colgan, et al., 1990; Dale, et al., 1999; Falanga, et al., 1999) were multi- 
centre trials with treatment based in the community. Schurmann and Eberhardt 
(1986) did not report the setting. Barbanno (1992) was a single centre study and the 
pardcipants received the majority of treatment within the community, but were 
treated in hospital for the first seven days after randomisation. During this period, 
the pamcipants received either a twice-daily dose of pentoxifylline 200mg via the 
intravenous route or a matching placebo. This was in addition to pentoxifylline 
1200mg in three divided doses via the oral route or a matching placebo. Barbarino 
(1992, p548) also tested each patient for "individualised reqonsiveness to  the active 
treatment" and then underwent a washout period of two weeks duration prior to the 
study commencing. Schurmann and Eberhardt (1986), Colgan, et al. (1990), Dale, et 
al. (1999) and Falanga, et al. (1999) all compared pentoxifylline 1200mg daily in three 
divided doses (400mg) with a matching placebo. Additionally, Falanga, et al. (1999) 
compared pentoxifylline 2400mg daily in three divided doses (800md with a 
matching placebo. 
The trials varied as to the investigators' treatment of participants with multiple ulcers. 
Colgan, et al. (1990) reported 18 patients in the treatment group and 24 in the 
control group had other ulcers, although it is not reported if this was on the same leg 
as the reference ulcer. The largest ulcer was used as the reference ulcer if it was 
within 2-15cm in diameter, and the number of participants with healed reference 
ulcers within 24 weeks were reported. However, only 2 participants with multiple 
ulcers (one in each group) had an additional ulcer still present after the reference 
ulcer had healed. Dale, et al. (1999) and Falanga, et al. (1999) used one leg as the 
reference leg and did not categorise the participant as healed unless all ulcers on the 
reference leg were completely re-epitheliased within 24 weeks of treatment. 
Schurmann and Eberhardt (1986) and Barbarino (1992) reported the area of 
ulceration, but not the number of ulcers for each participant. The authors did not 
record how multiple ulcers (if any) were treated. 
Methodological Quality of Included Studies 
Studies varied in quality and, or reporting of methods. All studies were described as 
randomised controlled u-ials, although randomisation strategies were reported in only 
two studes (Colgan, et al., 1990; Dale, et al., 1999) and allocation concealment in one 
(Dale, et al., 1999) Four trials were double-blind, although only Dale, et al. report 
how this was achieved (Prescott, et al, 1998). Schiirmann and Eberhardt (1986) was 
described as a single-blind trial, although it is not reported whether the participants, 
investigators or assessors were blinded. None of the trials reported any unblinding, 
so it was assumed blinding was satisfactory. Inclusion criteria were reported in all but 
1 trial (Schurmann & Eberhardt, 1986), although this trial stipulated varicose and 
postthrombotic ulcers in the paper's title. Exclusion criteria were reported in this 
trial, although one other study did not do so (Colgan, et al., 1990). One trial did not 
report any data on baseline comparability (Schurmann & Eberhardt, 1986), althougin 
theauthors stated data was comparable, and baseline mean ulcer size was able to be 
calculated from outcome data (ulcer size at baseline and conclusion for each patient). 
All studies reported objective data from which comparisons could be established; 
data from Falanga, et al. (1999) had to be extrapolated from a life analysis table. Two 
studies reported apeon' sample size calculations and the use of intention to treat 
analysis (Dale, et al., 1999; Falanga, et al., 1999). Falanga, et al. (1999) used intention 
to treat analysis for all patients who had enrolled and for whom one follow-up visit 
was documented. This excluded 2 participants from the final analysis. Three other 
studies either had no withdrawals (Barbarino, 1992; Schiirmann & Eberhardt, 1986) 
or included the withdrawals in the analysis as treatment failures (Colgan, et al., 1990). 
The included studies were assessed using following quality criteria and each study is 
reported below. 
U Inclusion and exclusion criteria 
Aprion' sample size calculation 
Method of randomisation 
Allocation concealment 
U Baseline comparability of groups 
U Blinding 
Appropriate outcome measures 
Analysis by intention to treat 
Schiimann and Eberhardt (1986): 24 participants in 2 arms; inclusion criteria not 
reported; exclusion criteria listed; a prion' sample size calculation not reported; 
method of randomisation not reported; allocation concealment unclear; baseline 
comparability data not reported, although age, weight, height and ulcer history stated 
as being comparable; single-blind randomised controlled trial; appropriate outcome 
measures reported (ulcer size for each patient at baseline and trial completion); 
analysis by intention to treat unclear, but no patients withdrew. 
Colgan, e t  al. (1990): 80 patients in 2 arms; inclusion criteria stated; exclusion criteria 
not listed; aprian' sample size calculation not reported; randomisation by balanced 
blocks of eight in separate lists for each centre; allocation concealment unclear; 
groups comparable for age, sex, mean ulcer duration, mean ulcer size, resting ankle- 
brachial index (AB9 and Basal Metabolic Index (BMq; double-blinding used; 
appropriate outcome measures reported (numbers of ulcers healed); analysis by 
intention to treat unclear, but withdrawals included in results as treatment failures. 
Barban'no (1992): 12 patients in 2 arms; inclusion and exclusion criteria stated; apnon' 
sample size calculation not reported; method of randomisation not reported; 
allocation concealment unclear; groups comparable for age, sex, mean duration of 
ulcer, mean ulcer sue and resting ABk double-blinding used; appropriate outcome 
measures reported (ulcer size for each patient at baseline and trial completion); 
analysis by intention to .treat unclear, but no patients withdrew. 
Dale, e t  aL (1999):' 200 patients in 2 arms within a factorial trial; inclusion and 
exclusion criteria stated; a priori sample size calculation reported (80% power to 
detect a 20% difference in treatment effects at p<0.05) (Prescott, et al, 1998); 
randomisation by sequential sealed opaque envelopes; allocation concealment 
adequate; groups comparable for age, sex, median duration of ulcer and median ulcer 
size at baseline; double-blinding used; appropriate outcome measures reported 
(numbers of ulcers healed); analysis by intention to treat. 
1 Information regarding this tda l  mas obtained from two sources; this source should be assumed to be 
the primary xeport udess indicated othenvise. 
Fukzngu, e t  uL (1999): 131 patients in 3 m s ,  129 included in analysis; inclusion and 
exclusion criteria clearly stated; upriori sample size calculation reported; method of 
randomisation not reported; allocation concealment unclear; groups comparable for 
age, sex, mean duration of ulcer, mean resting AB1 and numbers of ulcers per 
participant at baseline; double- blinding used; appropriate outcome measures 
reported (numbers of ulcers healed, median time to healing), but outcome measure 
reported using life-analysis table requiring results to be estimated from table; analysis 
by intention-to-treat. 
Comparisons of Studies 
The majority of studies reported either complete healing of the reference ulcer or all 
ulcers on the reference leg as the primary outcome, or provided individual data from 
which proportions healed could be calculated. In one study (Falanga, et al., 1999) 
proportions healed were extrapolated from a life-analysis table. The principal 
reviewer and one CO-reviewer (JW) independently determined and agreed upon the 
estimate. Falanga, et al. (1999) also compared two different doses of pentoxifylline 
(1200mg and 2400mg daily) with the placebo. For the purposes of this analysis, the 
two treatment arms were added together; sensitivity analyses were conducted to test 
the impact of this. Falanga, et al. (1999) also excluded 2 participants from the analysis 
after randomisation despite stating analysis was by intention-to-treat. The report did 
not identify which group they were excluded from. In order to avoid any over- 
estimation of treatment effect associated with this action, the excluded participants 
were included in the treatment as treatment failures, thus altering the denominator 
only. For the analysis of adverse effects, the 2 excluded participants were included as 
having suffered side effects, thus altering the numerator and the denominator. 
Five studies (Schiirmann & Eberhardt, 1986; Colgan, et al., 1990; Barbarino, 1992; 
Dale, et al., 1990; F a l a n s  et al., 1999) compared pentoxifylline to placebo with 
compression as a standard therapy. All trials reported complete healing as a primary 
outcome. The results are presented graphically in the Peto tables. A fmed effects 
model was used to combine the 5 trials, the pooled relative risk (RR) was 1.30 
(95%CI 1.10-1.54) indicating a significantly greater likelihood of complete healing 
occurring if pentoxifylline is used in addition to compression bandaging (F&m 4, see 
below). The result was robust to combination using a random effects model, although 
the result just attained significance @R 1.32, 95%CI 1.01-1.71). However, the 
absence of significant heterogeneity (Chi-square 6.36, df=4, p=0.17) suggests 
combination by faed effects model is appropriate 
. . 
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The comparison was not sensitive to exclusion of the 2400mg arm from Falanga, et 
al. (1999) (RR 1.31, 95%CI 1.10-1.57; Figure 5) or the exclusion of Schiirmann and 
Eberhardt (1986), the sole single-blind study (RR 1.32, 95%CI 1.12-1.57; Figure 6). 
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Three of the five trials repoaed treatment took place in a community or outpatient 
setting. Schiirmann and Eberhardt (1986) did not report a setting and participants in 
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Barbarino (1992) spent 7 days as hospital inpatients receiving both intravenous and 
oral treatment. The comparison was not sensitive to inclusion of only trials that 
reported outpatient treatment alone (RR 1.30, 95%CI 1.09-1.54; F&un 7) or oral 
treatment only trials (RR 1.28, 95%CI 1.08-1.51; F&un 8). Three of the mals 
reflected international prevalence studies with a greater ratio of female to male 
participants enrolled. Schiirmann and Eberhardt (1986) did not identify the sex of 
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their participants and Falanga, et al. (1999) had a greater ratio of male to female 
C01g8n 1990 23138 12142 
Dale 1999 65 H01  52 199 
Falanga 1999 61 186 28 145 
Schijlman 1986 2112 3112 
participants despite being a 14 centre mal. The significance of the comparison was 
- 11.0 2.12[1.23,3.651 
t 507 1.23[0.97.1.551 
C 35.5 1.14[0.87,1.491 
2.9 0.67[0.13,3.301 
not sensitive to exclusion of this trial, although the precision was influenced (RR 
1.39; 95%CI 1.12-1.73; Figure 3). 
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Three trials excluded participants with diabetes, a fourth did not speci5 whether 
diabetic participants were excluded (Schiirmann & Eberhardt, 1986), and a fifth 
(Colgan, et al., 1990) reported including diabetic participants and the group to which 
they were randomised in a letter regarding the trial (Colgan, 1990b). Exclusion of the 
trial which did not report exclusion of diabetics (Schiirmann & Eberhardt, 1986) and 
reallocation of three treatment successes as treatment failures in the pentoxifylline 
group in Colgan, et al. (1990) to test the worst case scenario had little impact on the 
summary relative risk (RR 1.29,95%CI 1.09-1.53; Ftgure 10). 
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Two trials (Barbarino, 1992; Schiirmann & Eberhardt, 1986) had a duration of 8-12 
weeks and three, a duration of 24 weeks (Colgan, et al., 1990; Dale, et al., 1999; 
Falanga, et al., 1999). The summary odds ratio for trials of 8-12 weeks duration was 
not significant with a relative risk 0.71 (95%CI 0.16-3.21). 
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The greater numbers of participants were involved in the trials of 24 weeks duration. 
The summary relative risk for these trials was 1.30 (95%CI 1.09-1.54; Figure 12). 
Heterogeneity was not significant and the exclusion of the 2400mg arm of Falanga et 
al (1999) also had little impact (RR 1.31, 95%CI 1.09-1.56; Figc~re 13). 

Chapter 5. DISCUSSION 
There is no gold standard test for venous ulceration. Diagnosis is made 
probabilistically by excluding other likely causes of ulceration, which can be 
complicated by the presence of CO-morbidities. Baker, et al. (1991) noted that 5.5% 
in sampled venous ulcers, the participants had diabetes, whilst 6.7% had rheumatoid 
arthritis, both diseases that are associated with leg ulceration. Nelzbn, et al. (1994) 
noted a similar number (8%) having diabetes in their study. Several studies in this 
meta-analysis attempted to limit the potential impact of mixed aetiology ulceration by 
excluding participants with CO-morbidities such as diabetes (Barbarino, 1992; Dale et 
al., 1999; Falanga et al., 1999). However, Schiirmann and Eberhardt (1986) did not 
specify CO-morbidities as an exclusion criteria and Colgan, et al. (1990), whilst not 
specifying their exclusion criteria, later identified that 3 participants included in the 
treatment group had diabetes (Colgan 1990). Arguably, this makes the trial more 
valuable as it is likely to reflect what occurs in clinical practice, although it potentially 
dilutes inferences drawn about the casual relationship between pentoxifylline and 
ulcer healingwhen a single trial is considered. 
The means of diagnosis differed between the studies. Schiirmann and Eberhardt 
(1986) did not specify how the diagnosis of venous ulceration was made, although 
the study title makes it clear it was a trial involving participants with 'varicose' or 
post-thrombotic leg ulcers. The remaining four studies provided details of the 
diagnostic assessment, including the reporting of objective tests; three of the studies 
also specified a clinical history and examination as part of the diagnostic work up 
(Colgan, et al., 1990; Dale, et al., 1999; Falanga, et al., 1999). Given Barbarino (1992) 
identified the objective testing incorporated in their work up, it is improbable that 
the investigator did not also conduct a clinical history and examination. 
The objective measures varied between the trials. Venous disease was determined 
using Doppler ultrasound measurement of venous reflux (Barbarino, 1992; Dale, et 
al., 1999; Falanga, et al., 1999) and the measurement of venous hypertension at the 
ankle (Barbarino, 1992). Doppler ultrasound measurement of the Ankle-Brachial 
Index' to rule out arterial insufficiency was utilised, with the threshold of 0.8 usually 
reported (Barbarino, 1992; Colgan, et al., 1990; Dale, et al., 1999). Falanga et al 
1 See page 43 
(1999) reported a threshold of 0.5, although the mean AB1 for both control and 
treatment groups was 1.1, indicating aaerial insufficiency was not prevalent in their 
participants. Therefore, the reviewers believed that at the very least, the majority of 
participants had exclusively venous disease. Even if Schiirmann and Eberhardt 
(1986), who did not report their inclusiori criteria and the three participants from 
Colgan, et al. (1990) with diabetes were excluded from the analysis, 418 out of 447 
met stringent inclusion criteria. 
Compression significantly increases the proportion of healed ulcers in people with a 
venous aetiology. Multilayer bandaging (3 layer, 4 layer, Unna boot2) has been found 
to be more effective than single layer systems, although no specific type of multilayer 
system was favoured (Cullum, Fletcher, Nelson, & Sheldon, 1999). Various 
multilayer systems were used by the included trials, Unna boot (Falanga, et al., 1999), 
and 2 layer systems (Barbarino, 1992; Colgan, et al., 1990). Dale, et al. (1999) used 
both single and 4 layer systems balanced in a factorial trial while Schiirmann and 
Eberhardt (1986) did not specify what type of compression bandaging was used in 
their trial. Attempts by the reviewer to contact the investigators by mail and email 
were not successful. With the exception of Schiirmann and Eberhardt (1986), the 
direction of effect ali favoured pentoxifylline suggesting a treatment effect that was 
independent of the type of compression bandaging used. The summary relative risk 
was 1.30 (95% C1 1.10-1.54) and this was not sensitive to dose, type of blinding, 
route of drug, sex of the participants, or inclusion of the participants excluded by 
investigators after randomisation. The summary relative risk for adverse effects was 
not significant (TG3 1.12, 95% C1 0.79-1.66), although the incidence of adverse effects 
was higher in the pentoxifylline group. This result was not sensitive to dose. In the 
studies that described the adverse effects, the most frequent were gastrointestinal 
disturbances (34 percent). Of the two studies that did report reasons for withdrawals 
(Colgan, et al., 1990; Dale, et al., 1999), 7 of 14 cited the reason as side effects. This 
could suggest that many participants tolerated adverse effects, although those 
withdrawing because of adverse effects represented only 33 percent of paaicipants in 
the treatment groups whom experienced a side effect. Additionally, one of the 
smaller studies reported no withdrawals (Barbarino, 1992), despite reporting 
incidence of adverse effects (2 out of 6 participants suffered transient nausea and 
headaches). Thus it would seem that the majority of those who experienced adverse 
Unna boot is a multilayer bandage that consists of a zinc impregnated bandage and an elastic 
bandage i.e. Coban. 
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effects tolerated them. 
The majority of people with venous leg ulcers are managed in the community 
(Callam, Ruckley, Harper, & Dale, 1985). One study (Barbarino, 1992) provided a 
combination of inpatient treatment for the first 7 days following entry into the trial 
and outpatient treatment for the following 60 days. Schurmann and Eberhardt (1986) 
did not report the study setting for their trial. The summary statistic was not sensitive 
to the exclusion of these trials, suggesting the treatment is effective in a community 
setting. As noted earlier, Colgan et al (1990) included 3 diabetic participants in the 
treatment groups without identifying their treatment outcomes. Schurmann and 
Eberhardt (1986) did not report that diabetic participants were included or excluded. 
The remaining trials excluded people with diabetes from participation. Exclusion of 
Schurmann and Eberhardt (1986), and the reallocation of 3 treatment successes in 
the pentoxifylline arm in Colgan et a1 (1990) to treatment failure tested the sensitivity 
of the summary statistic to the worst case scenario. The summary relative risk was 
not sensitive to this test @R 1.29, 95% C1 1.09-1.53). 
The duration of treatment is an important clinical consideration. Two trials had a 
treatment maximum of 8-12 weeks (Barbarino, 1992; Schurmann & Eberhardt, 
1986). Combination of these trials produced a statistically non-significant result. The 
remaining 3 trials were of 24 weeks duration, with participants treated until complete 
healing or a maximum of 24 weeks. The summary statistic favoured pentoxifylline 
@R 1.30, 95% C1 1.09-1.54) and was not sensitive to the exclusion of the 
participants in Falanga, et al. (1999) who received the 2400mg dose. Examination of 
the life tables published in Colgan, et al. (1990), Dale, et al. (1999) and Falanga, et al. 
(1999) reveals a treatment effect does start to appear at 8-12 weeks; healing rates at 8 
weeks were similar in Colgan, et al. (22% for pentoxifylline versus 20% for controls) 
and Dale, et al. (30% for pentoxifylline and 22% for controls). Only in Falanga, et al. 
(1999) did a divergence in healing rates appear earlier, with 8 week healing rates 
substantially different (50% for the 2400mg dose group, 45% for the 1200mg dose 
group and 22% for the control group). The combined results for these trials, 
excluding the participants receiving the 2400mg dose of pentoxifylline, showed an 
absolute difference of 16.1   er cent^, giving a 'number needed to treat' (NNT) to 
3 The absolute difference is obtained by subtracting the desired outcome m the treatment group from 
the desired outcome in the control p u p .  
obtain one more healed ulcer when using pentoxifylline of 7 (95% C1 4-16).4 Such a 
low NNT is more desirable than a high NNT, as it indicates only a small number of 
patients need to be treated to obtain one desired outcome. However, obtaining 
NNTs from meta-analysis can be misleading as just grouping the number of 
participants in the treatment aim and deriving a NNT ignores differences introduced 
by varying trial durations, doses, trends in incidence and the clinical setting (Smeeth, 
Haines, & Ebrahim, 1999). It  is also possible that the NNT may contravene the 
statistical assumptions underpinning combination by a fmed or random effects 
model. The fmed effects model assumes variations in trial samples are the result of 
random error, and the samples are all drawn from the same population. The random 
effects model assumes that the baseline characteristics reflect different populations, 
riot random error. Thus combination of results derived from a random effects model 
contradicts the inherent assumption that the samples are drawn from different 
populations. Clarke and Oxman (1999) suggest that the NNT is an acceptable 
calculation when the duration of trials and dosages are the same, as is the case with 
the three trials from which this NNT was obtained. 
Dosage is also an important clinical consideration. All but one trial utilised a 1200mg 
dose of pentoxifylline, this dose being that used in earlier trials with intermittent 
claudication. Falanga, et al. (1999) compared both 1200mg and 2400mg daily doses 
of pentoxifylline with the placebo. The rate of reported adverse effects was higher in 
the 2400mg group with 34.9 percent suffering adverse effects compared to 28.9 
percent in the 1200mg group, although the withdrawal rate was similar in both 
groups. Virtually no difference between the two treatment groups was noted in the 
proportions healed at 24 weeks (74 percent for the 1200mg groups versus 72 percent 
for the 2400mg group). However, the investigators noted the median time to healing 
was lower in the 2400mg group at 71 days compared with the 83 days in the 1200mg 
groups. Median time for healing in the placebo group was 100 days. This suggests 
that although there appears to be no dose-dependent response in the numbers of 
people with healed ulcers, there may be a relationship between dose and time to 
healing. However, no other study reported either average or median time to healing 
and this suggested relationship would need further testing before such an inference 
could be stated. 
' The NNT is calculated by obtaining the i n ~ ~ r s e  of the absolute risk difference; the measure provides 
an e s h a t e  of the number of people who must be treated in order to obtain one beneficial outcome. 
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The cost-effectiveness of treatment wit11 pentoxifylline and compression has only 
been considered in association with one trial (Dale, et al., 1999). A full report of this 
is not yet available, although an abstract has been published in conference 
proceedings. Bosanquet, Franks, Brown, Straub, Harper and Ruckley (1995) reported 
that the total cost of ulcer care was greater in the placebo group CC;1,787) compared 
with pentoxifylline 1200mg CC;1,524), concluding that pentoxifylline was more cost- 
effective and healed more ulcers. However, this abstract presented no information 
on how the cost of treatment was assessed and thus, it is difficult to compare this 
result with even local cost environments. 
Meta-analyses have become important because many mals are small and do not ha?re 
sufficient power to detect small treatment effects. However, meta-analyses can 
mislead. LeLorier, Gregoire, Benhaddad, Lapierre & Derderian (1997) compared the 
results of 12 large (n>1000) randomised controlled trials (RCTs) with 19 meta- 
analyses published earlier on the same question. A total of 40 primary and secondary 
outcomes were measured and all large RCTs had to meet the a pnbn' power 
calculation specified by the trial investigators. LeLorier, et al. (1997) found agreement 
between the two methods was only fair (kappa=0.35, 95%CI 0.06-0.64), with the 
positive and negative predictive values of the meta-analyses 68 and 67 percent 
respectively. This would have led to adoption of ineffective treatments in 32 percent 
cases and rejection of effective treatments in 33 percent of cases. Although the 
difference in point estimates was significant in only 5 out of 40 comparisons, in each 
case a statistically significant effect was found by one method and no significant 
effect was found by the other method. Villar, Carroli and Belizin (1995) conducted a 
similar analysis with 30 meta-analyses in perinatal medicine. The results of the largest 
trial were removed from the meta-analyses, comparisons recalculated and compared 
to the result of the largest mal removed from each meta-analysis. The investigators 
found 24 meta-analyses correctly predicted the direction of effect for the largest trial, 
but in only 18 were both the same direction and statistical significance predicted. 
Publication of the Fourth International Study of Infarct Survival (ISIS-4) confirmed 
that meta-analyses can mislead. A meta-analysis of seven published mals (n=1301) 
concluded that magnesium was an effective simple and safe treatment which reduces 
mortality following acute myocardial infarction (Yusuf, Koon, & Woods, 1993). The 
ISIS-4 Collaborative Group (1995), with 58,050 participants, found no effect for 
magnesium sulphate. In examining why this might be so, Egger and Davey Smith 
(1995) found four possible causes. Firstly the meta-analysis had not included non- 
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English language studies and the search strategy had not incorporated handsearching. 
Extending the search to include non-English language studies and using 
handsearching, Egger and Davey Smith (1995) found 5 small studies missed by the 
meta-analysis. Secondly, publication bias was evident in the distribution of the 
literature. This can be examined using funnel plots, in which effect sizes are plotted 
against sample size. If there is no publication bias, the plot should resemble an 
inverted symmetrical funnel, as the results of smaller studies are more scattered 
around the averaged effect size than those of the larger studies.' A funnel plot of 
Yusuf, et al. (1993) revealed a highly asymmetrical plot, suggesting publication bias. 
Some of the trials in the meta-analysis were not analysed by intention-to-treat; when 
this was recalculated the significant differences became non-significant. Such biases 
in the included trials were the third potential reason for the difference between 
Yusuf, et al. (1993) and ISIS-4. The fourth possibility was that with so many meta- 
analyses now being conducted, a few will produce misleading results by chance. 
Should the concern that meta-analyses can mislead influence the interpretation of 
meta-analyses? LeLorier, et al. (1997) suggest it should. They believe that readers 
should go beyond simple point estimates when interpreting a meta-analysis. Instead 
the reader should investigate the included studies and look closely for consistency in 
the results. If the results of most included trials are on the same side of the forest 
plot, then the meta-analysis merits more confidence than if the results are distributed 
across the line of no effect. A similar point is made by Thompson and Pocock 
(1991). Examination of the forest plot for the five included trials here shows that 
four are on the same side of the line of no effect. This combined with the absence of 
significant heterogeneity should enhance confidence in the results of the meta- 
analysis. 
A funnel plot of the studies reveals a symmetrical shape ( F & m  16, see page 59) 
suggesting an absence of publication bias. However, the small number of studies and 
low power of this statistical technique at the best of times, means that this finding 
should be regarded with considerable caution (Clarke & Oxman, 1999). 
Implications for Clinical Practice 
Although compression has improved rates of healing in people with venous ulcers, it 
5 The prevailing assumption is that larger studes are more precise and therefore likeljr to be doser to 
the average effect nze. 
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is not effective in all instances. A recent cost-effectiveness study modelling the costs 
of various bandaging regimens and service delivery models drawn from a randomised 
controlled trial, assumed that 29% of ulcers would remain unhealed after 52 weeks 
treatment (Carr, Philips, & Posnett, 1999). More importantly, the study assumed that 
no more people healed after week 24 when treated with compression. People whose 
ulcers do not heal remain a significant cost to the health system (Ebsanquet, 1992); 
the overall costs must be greater when the impact on people's own lives is 
considered. Phillips, et al. (1994) reported that 76 percent of participants with an 
ulcer reported their fmancial situation was adversely affected by the presence of 
ulceration. Therefore, the addition of any adjunctive treatment, which improves rates 
of healing, especially in those with ulcers refractory to conventional treatment, is 
desirable. The two studies within this review that either stipulated therapy resistant 
ulcers as an inclusion criterion (Barbarino, 1992) or drew from a population of 
therapy resistant patients (Colgan, 1990b) found an effect in favour of pentoxifylline. 
Although statistical heterogeneity was non-significant, the clinical heterogeneity of 
these two mals was such that combination was unlikely to provide any useful 
information, particularly as the number of mals precluded sensitivity testing. 
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In summary, pentoxifylline is a useful adjunct to compression bandaging in the 
treatment of venous ulcers. The absence of any definitive evidence on the cost- 
effectiveness or improved time to healing suggests that it should not be considered as 
routine treatment. However, patients with ulcers resistant to compression therapy 
may benefit from adjunctive pentoxifylline. This will be pamcularly important as the 
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general population ages; the incidence and prevalence of ulceration increase with age 
(Baker, et al., 1991; Nelzkn, et al., 1991). Minor gastrointestinal disturbances (nausea, 
vomiting and diarrhoea) are the most frequent adverse effect, but adverse effects 
seem likely to be tolerated by patients in the majority of cases. Although nurses are 
not able to prescribe pentoxifylline, knowledge of additional effective therapies is 
important in order to be able to inform patients as to treatment options, particularly 
when conventional therapy, such as compression, is ineffective. 
Implications for Research 
Methodologically the studies varied in quality and/or reporting of method. Although 
methodological quality and reporting quality can be confused, inadequate reporting 
of methods does not assist methodological assessment. All included studies were 
described as randomised controlled trials, although randomisation strategies were 
reported in only two studies (Colgan, et al., 1990; Dale, et al., 1999), and allocation 
concealment in one (Dale, et al., 1999). Four studies were described as double-blind 
comparisons (Colgan, et al., 1990; Barbarino, 1992; Dale, et al., 1999; Falanga, et al., 
1999), although only one study described how this was achieved (Dale, et al., 1999). 
Blinding was described in a personal communication from the principal author in 
Falanga, et al. (1999). One trial was described as a single blind comparison, but again 
how this was achieved was not described (Schiirmann & Eberhardt, 1986). None of 
the five trials reported any unblinding of patients, so it was assumed blinding was 
satisfactory. Inclusion criteria were reported in all but one study (Schiirmann & 
Eberhardt, 1986), although this trial stipulated varicose and post-thrombotic ulcers in 
the paper's title. Exclusion criteria were reported in the trial and in all one other 
trials, bar one (Colgan, et al., 1990). One trial did not report any baseline data on the 
comparability of groups, although the authors reported the baseline data was 
comparable (Schiirmann & Eberhardt, 1986). However, mean ulcer size at baseline 
favoured the control group (pentoxifylline 5.4 cm2; control 2.5cm2). 
All studies reported objective outcome data from which comparisons could be 
established. Two studies (Dale, et al., 1999; Falanga, et al., 1999) used complete 
healing on single legs as the reference for the trial endpoint. Neither of these trials 
noted whether any participants had bilateral ulceration. Colgan, et al. (1990) used a 
single ulcer as the reference ulcer, where multiple ulcers were present. They noted 
that in all but 2 participants with multiple ulcers (one in each group), all other ulcers 
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had healed by the time the reference ulcer had healed. Neither Schurmann and 
Eberhardt (1986), nor Barbarino (1992) identified whether their participants had 
multiple ulcers, although both recorded the total area of ulceration present in each 
participant. The use of single ulcers and legs as references for recording trial 
endpoints assumes that each ulcer heals independently of all others. This cannot be 
assumed when the therapy is systemic. Different bandaging pressures on different 
legs in participants with bilateral ulceration may confound healing. However, this 
reflects the clinical reality and for a truly accurate estimate of clinical effectiveness to 
emerge, all a participant's venous leg ulcers, regardless of site, should be healed for a 
positive outcome to be recorded. 
Data from Schurmann and Eberhardt (1986) and Barbarino (1992) was calculated 
from the data at baseline and trial conclusion reported for each participant. Data 
from Falanga, et al. (1999) was extrapolated from a life analysis table; the co- 
reviewers (AJ/JW) independently calculated and agreed upon this data. Two studies 
reported apriori sample size calculations and the use of intention to treat analysis 
(Dale, et al., 1999; Falanga, et al., 1999). Falanga, et al. (1999) used intention to treat 
analysis for all patients who had enrolled and for whom one follow-up visit was 
documented. This excluded 2 participants from the final analysis. The three 
remaining trials either had no withdrawals (Barbarino, 1992; Schurmann & 
Eberhardt, 1986), or included the withdrawals in the analysis as treatment failures 
(Colgan, et al., 1990). The non-English language study (Schurmann & Eberhardt, 
1986) reported less methodological detail than did the English language studies. 
However, with exception to Dale, et al. (1999), attempts had to be made to contact 
all the studies' authors to gain further information. This was successhl only in the 
case of Falanga, et al. (1999) and even then, not all the information requested was 
provided. 
The important messages for future studies are: 
1. The CONSORT (Consolidated Standards of Reporting Trials) statement should 
be used as a guideline for reporting (Beg, et al., 1996). A group consisting of 
editors, clinical epidemiologists, and statisticians wrote this statement in 1995, in 
an effort to improve the quality of written reports of randomised controlled 
trials. It has been adopted by journals such as JAMA and BMJ. 
2. Recruitment numbers should be based on aprion' sample size calculation given 
that the likely treatment effect can now be inferred. 
3. Treatment should include multi-layer compression bandaging as a standard 
therapy, unless the trial is assessing effectiveness in people unable to tolerate 
compression. 
4. Where mulaple ulcers exist, complete healing of all leg ulcers, even bilateral, 
should be the endpoint in the drug trial. 
5. Shoa duration trials should be avoided, particularly as there is the suggestion that 
a treatment effect only begins to appear after 8-12 weeks of treatment. 
6. Analysis should be by intention-to-treat of all participants following 
randomisation. Intention to treat analysis is generally taken as "inchdng all 
patients, regardLess qwhetber t h y  actuaq sati$ed the ently mtena, the treatment received and 
subsequent withdrawal or deviadon fm thepmtoml" (Hollis & Campbell, 1999, p670). 
7. Economic evaluations should be incorporated into mals in order to determine 
the cost-effectiveness of treatment. 
Chapter 6. CRITICISM AND NON-RANDOM REFLECTIONS 
Meta-analysis has not been without its critics. Criticism has centred on the statistical 
combination of studies and it has been argued that meta-analysis combines 'apples 
and oranges', that garbage in leads to garbage out, and that the technique 
camouflages good scientific method with bad (Eysenck, 1978; Wolf, 1986; Wachter, 
1988; Eysenck, 1994). These challenges have originated from opposition to the 
method in social sciences. When Smith and Glass (1977) conducted the first meta- 
analysis on psychotherapy outcomes, they included studies of any type of 
psychotherapy and all the literature they could identify that incorporated a control 
group, irrespective of methodologic quality. They identified 375 studies of 18 
different treatments, with 40,000 treated and untreated participants, the treatment 
groups having received an average of 20 hours therapy by therapists with an average 
of 2.5 years experience. The participants themselves were a diverse group ranging 
from severe neurotics to people experiencing existential discomfort and a range of 
outcomes were reported. 
The clinical heterogeneity of the studies in Smith and Glass's, meta-analysis was 
considerable, leading to the 'apples and oranges' charge: the treatments were 
different, the study designs were different and the outcomes measured were 
different. Yet the authors were investigating the effectiveness of psychotherapy in 
general, not particular therapies, and hence the inclusive approach. The authors had 
been also inclusive in recognition that non-inclusion could introduce bias in the 
manner of traditional reviews. 
The effectiveness of psychotherapy had troubled psychology and had been the focus 
of many investigations (Hunt, 1997, particularly following the publication of a 
review challenging its effectiveness (Eysenck, 1952). Eysenck compared the results of 
I9 studies of neurotic patients treated by psychotherapy with 2 samples of neurotics 
who received no treatment, and found that approximately two-thirds of neurotic 
patients would recover after 2 years, whether or not they were treated. A major 
criticism of this work was that it lumped together dissimilar patient groups and 
treatments. This was exactly the challenge that Eysenck, a major critic of meta- 
analysis made of Smith and Glass (1977) when he suggested meta-analysis combined 
'apples and oranges' and thus was an =ercise in 'mega-silliness' (Eysenck, 1978; 
Eysenck, 1994). Eysenck is also reported to have called meta-analysis an exercise in 
mega-imbecility (Hunt, 1997). 
Central to Eysenck's criticism are issues of methodological rigour, principally 
concerns about heterogeneity, and the inclusion of methodologically poor studies. 
These concerns are not without due cause. Averaging studies which are dissimilar in 
demography, interventions, and outcomes, or, in other words, heterogenous, may 
produce misleading results and the inclusion of poor quality studies, even m a 
homogenous sample of studies, can lead to over-estimation of treatment effects as 
discussed previously (Egger & Davey Smith, 1995; Moher, et al., 1998). This 
vulnerability has resulted in systematic review, with very specific questions, inclusion 
criteria, and methodologic assessment, being incorporated into meta-analysis (Gerbag 
& Horwitz, 1988; Cook, Sackett, & Spi.tzer, 1995; NHS Centre for Reviews and 
Dissemination, 1996). Caution should still be exercised when reading a meta-analysis, 
particularly one that includes a small number of studies. With small numbers, it 
cannot be certain that there has been an adequate sampling of the domain of 
potential participants, although this is offset by evidence of homogeneity in research 
questions, study designs and direction of effect. Meta-analysis requires methodologic 
vigilance, but should not be rejected as an exercise in 'mega-silliness'. The 
methodology has matured, addressed issues of rigour and now has a central place in 
research, being an essential element in effectiveness research. Eysenck too seems to 
have accepted that mewanalysis has a place "but on& fattention ispaid t o  the conditions 
that must be fu@LLed in order to make the estimates @pkcabLe" (Eysenck, 1995, p35). 
Personal Reflections on Meta-analysis 
Systematic review and meta-analysis is a time consuming process, with much time 
committed to awaiting the results of literature searches, translating non-English 
language studies and seeking further information from trialists. Dickson and 
Entwistle (1996) reported spending 94 days searching the literature for a systematic 
review. Considerable amounts of time were also committed in this study to 
attempting communication wit11 investigators in order to clarify methodological 
issues not addressed in reports, seeking suitably qualified translators and funding for 
translations. Study reports may not be available in New Zealand, or even indexed in 
MEDLINE~, which tends to run 6 to 12 weeks behind actual publication. Falanga, et 
al. (1999) was identified by the Cochrane Wound Group Co-ordinator after 
electronic searching had been completed. The journal in which it was published is 
not held in New Zealand, but is available in Australia, although an interloan request 
revealed that Australian libraries had not yet received this issue. The principal 
author's email address was identified by searching the Boston University's website1 
and contact with the author duly produced a faxed imprint of the article. This was 
the only example of success using the Internet. Attempts to identify a contact for the 
authors of Schurmann and Eberhardt (1986) had very limited success. The 
employing institution of the corresponding author did have a website, but no list of 
staff contacts and it was clear from their response to an email query to the 
webmaster that communicating in English was not going to be successful in eliciting 
the necessary information. No other attempt to contact an author unknown to the 
reviewers was successful. It  has been previously noted that a centralised register of 
aids would assist systematic reviewers. I would add that difficulties in locating 
authors would be greatly assisted by the maintenance of a database of trialists' 
current addresses, or where tcialists are no longer available, identification of the 
location of the trial data and person(s) responsible for the data. 
Translations are an absolute necessity for the conduct of a full systematic review, but 
locating translators with an understanding of health sciences is not simple, even for 
European languages. Locating a translator for non-European languages is even 
harder. Although the Cochrane Collaboration does try to co-ordinate translations 
through the Italian Cochrane Centre, attempts to have Brazilian, German and Italian 
studies translated through this centre were not successful. The suggested Portuguese 
translator did not respond to emails, the Italian translation did not arrive, despite 
being organised, and the German translation was completed only because I had 
learnt that personal contact was important. I utilised the Cochrane Co-ordinator of a 
local, but unrelated Review Group to organise the German translation, as she said 
she had been successful at this in the past. Attempts to use senior students through 
the Romance Languages Department at the local university were unsuccessful, with 
students stating they could not translate the articles after having reviewed them. 
Consequently, funding had to be obtained to translate the Brazilian and Italian 
studies by commercial translators, only to have them ruled out of selection as a 
consequence. Neither of these translators had experience in the health sector, and 
1 A previous article by the author identified his academic association 
both required assistance, guidance and intuition from the principal reviewer, although 
this assistance was never acknowledged in the rates that we had to pay the 
translators. 
Nursing and Meta-analysis 
Pearcey (1995), in a survey of 398 nurses involved in education and clinical practice 
in a variety of settings, found that 93 percent were not satisfied with their research 
skills, despite 78 percent agreeing that the use of research findings could improve 
care or teaching. There was no significant difference in groups ordered by number of 
years trained and satisfaction with research skills, although staff on night duties did 
have significantly less satisfaction with their skills. The investigator noted that this 
was counter-intuitive to the perception that research is taught more extensively than 
ever before. The main self-perceived deficits were in locating, reading and evaluating 
research reports. In addition to little confidence in appraisal skills, most nurses also 
reported having very little time for reading research during their working day. 
Meta-analyses are one more tool for addressing the need to drive evidence into 
practice. In aggregating studies addressing a particular question, quality assessing the 
studies against methodologic criteria that are known to bias results in controlled 
studies, and summarising the evidence, meta-analyses are a reliable and valid means 
for addressing the needs of clinical practice. Nursing has used meta-analysis from the 
early 1980s, although nursing's adoption of the methodology has not been as fast or 
extensive as in medicine. The first meta-analysis conducted by a nurse examined the 
effects of a behavioural intervention on weight loss in obese patients and was 
indexed in 1982 (O'Flynn, 1982a). The first published mem-analysis was indexed in 
1983 (Devine & Cook, 1983). Early meta-analyses in nursing drew heavily on 
psychology to examine the effects of behavioural therapy (O'Flynn, 1982a), psycho- 
educational interventions on hospital length of stay (Devine & Cook, 1983), and pre- 
operative instruction (Hathaway, 1986). 
Droogan and Cullum (1998) explored the extent to which there existed systematic 
reviews of nursing effectiveness2, as part of the National Health Service Research and 
Development programme. Using electronic searching of computerised databases and 
2 The term is used synonymously with meta-analysis by these authors. 
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handsearching up to 1994, they identified a total of 36 papers, which specified either 
a question, a search strategy or reported the means of synthesis. Nineteen reviews 
met all 3 criteria, with the majority of these being published after 1990. Seven of the 
19 addressed patient education, perhaps reflecting the continuing influence of 
psychology on the use of meta-analysis in nursing. In 1982, O'Flynn (1982b, p316) 
had noted that meta-analysis was "an externeh efiient approach to the integration of.rtu&es 
and when appmpriate& wed wi7l expedte nursing's future endeavors [sic]." As evidenced by 
Droogan and Cullnm's (1998) search, few nurses had taken to the methodology and 
the promise O'Flynn had noted, leading Droogan and Cullum to comment that there 
are 
m a q  important topics notewady bJi their absence, with a p a u i g  ofrevie21~s dating 
to the organisation o f  care.. . 
(ibid., p18) 
Textbooks on research methodologies in nursing have been slow to alert nurses to 
either the place of meta-analysis or the role of systematic review in research, even 
very recent publications. Examination of nine texts published between 1986 and 
1999 (Hogstel & Sayner, 1986; Bums & Grove, 1987; Seaman, 1987; W~lson, 1989; 
/. 
Mateo & Kirchhoff, 1991; Burnard & Morrison, 1994; Robertson, 1994; LoBiondo- 
Wood & Haber, 1998; Polit & Hungler, 1999) found only four mentioned meta- 
analysis, and then with limited discussion and no criteria for critiquing the 
methodology (Bums & Grove, 1987; Wilson, 1989; LoBiondo-Wood & Haber, 1998; 
Polit & Hungler, 1999). No text mentioned systematic review. All the texts discussed 
the purposes of literature review, but rarely in terms of research synthesis. More 
commonly literature reviews were discussed as a component of preparing a research 
report. None of the texts that discussed meta-analysis did so with reference to it as 
an advance on narrative reviews. Efforts such as the Cochrane Collaboration, the 
Joanna Briggs Institute of Evidence Based Nursing, and the McMaster Nursing 
Effectiveness, Utilisation and Outcomes Research Unit are starting to encourage the 
conduct and dissemination of meta-analyses relevant to nursing practice. However, it 
is clear that both the number of systematic reviews and the number of nurses 
involved in their conduct needs to increase. Health care is delivered by 
multidisciplinary teams and systematic reviews should reflect this where appropriate 
(Droogan & Cullum, 1998). 
Chapter 7. CONCLUSION 
The project has used meta-analysis to investigate the effect of pentoxifylline on 
venous ulcer healing when used as an adjunct to compression therapy. Ten 
randomised controlled trials were identified, using a strategy that searched databases 
created from frequent and extensive electronic searching and handsearching of 
relevant journals, conference proceedings and other grey literature. Five studies meet 
apriori specified inclusion criteria, and were aggregated utilising computer software 
distributed for the purpose by the Cochrane Collaboration. The trials did not exhibit 
any significant clinical or statistical heterogeneity and were combined to produce a 
summary statistic. The relative risk favoured pentoxiijdline as an adjunct to 
compression bandaging, and this was robust to sensitivity analyses. Gastrointestinal 
disturbances are the most frequent adverse effect, but adverse effects appear to be 
tolerated by patients in the majority of cases. 
The absence of any definitive evidence on the cost-effectiveness or improved time to 
healing suggests that it should not be considered at routine treatment. However, 
patients with ulcers resistant to compression therapy may benefit from adjunctive 
pentoxifylline. This will be particularly important as the general population ages; the 
incidence and prevalence of venous ulceration increase with age. Although nurses are 
not able to prescribe pentoxifylline, knowledge of additional effective therapies is 
important in order to be able to inform patients as to treatment options, pamcularly 
when conventional therapy, such as compression, is ineffective. The implications of 
this project for future research were considered and recommendations for the 
conduct of research and presentation of research reports results were made, to assist 
with future meta-analyses. 
Nursing has yet to take up the early promise of meta-analysis, although a few nurses 
have conducted meta-analyses in areas of importance to nursing. Meta-analyses 
prepared by organisations such as the Cochrane Collaboration, will also inform and 
be of value to nursing practice. However, the requirement that valid meta-analyses 
incorporate as many studies as possible, irrespective of language, creates difficulties 
for their conduct, unless researchers are adequately supported to obtain translations. 
Such support could be improved, and would be greatly assisted by the maintenance 
of an international register of trialists with current contact addresses for occasions 
when clarification or further information is needed. 
A number of fertile areas for h r t l~e r  investigation have arisen through this meta- 
analysis. They include: 
1. Further work to determine the cost-effectiveness of pentoxifylline and 
compression bandaging. 
2. Further work to determine whether pentoxifylline is more effective on refractor{ 
venous ulcers. 
3. Further work to determine whether time to healing is dose dependent. 
EPILOGUE. Personal Reflections on Nursing Research 
There can be little question that systematic review and meta-analysis are of pragmatic 
use to nursing. But one of the many interesting questions raised by this project has 
been what is nursing research and could this project be considered such? Certainly 
the principal reviewer is a nurse by profession, but definition by this route only leads 
one to the misconception that research becomes nursing if conducted by nurses. The 
fallibility of this definition becomes obvious when it is considered in terms of logic 
. . 
statements: A is a nurse; A is conducting research; therefore, A is conducting nursing 
research. Yet a nurse conducting research in physical anthropology is unlikely to be 
conducting nursing research. Similarly, the use of particular methodologies does not 
make research nursing research. Nursing, in common with all the sciences and social 
sciences, employs a variety of methodologies developed by other disciplines, with the 
choice being determined by the type of phenomenon being investigated. For 
instance, causal relationships are best investigated using the randomised controlled 
trial, a methodology commonly associated with medicine, but which was developed 
for agricultural research. 
This leaves only the content or context of the research as being definitive. The 
content of this project is the investigation of a drug therapy, a modality normally 
associated with the practice of medicine, not nursing. Burns and Grove (1987) have 
noted that knowledge can be drawn from other disciplines and integrated into the 
practice of nursing; where such transdisciplinary sharing takes place "it is dzjimlt to 
know where the boundaries exist between nu~rring's knowledge base and those gother rk'saipLnesJ' 
(ibid. p21). In this project the key issue has been can a drug therapy assist in the 
healing of venous ulcers? Conventional treatments do not assist all people with leg 
ulcers and thus the use of pentoxifylline may benefit those who do not respond to 
conventional therapies alone. Nurses in the community are responsible for much of 
ulcer care (Callam, et al., 1985) and thus must be aware of other options where 
conventional therapies fail in order to adequately inform patients of what may be 
possible. This will be emphasised in New Zealand if prescribing rights are given to 
certificated nurses involved in aged care, as the incidence and prevalence of ulcers 
increases with age. The content of this project can be said to be of value to nursing, 
meeting McGowen's definition of nursing research, which is 
nsearch into thepm~ss ofdeli'ue~ o f  care, and the cli'nicaLpmblems that a n  
encountered in nursing practice 
(McGowen, 1994, pl). 
However, with nursing being at the nexus of patient care, it encounters many clinical 
problems that have been addressed by other disciplines, of which this project is but 
one example. Research into problems encountered by practitioners of nursing does 
not make the research nursing research. Thus, perhaps it is the context that is 
important. McGowen (1994) noted that unless the research addresses eveiyday issues 
associated with the practice of nursing, it cannot be considered nursing rese.xch. lvie:t. 
can investigation into the acmrdcy of digital thermometers be considered nursing 
research, even if conducted by nurses, in a nursing context? Accuracy of temperature 
readings is as important to general practitioners and parents as it is to the nurse. 
Burns and Grove (118'7) attempt to differentiate the contextual nature of nursing 
research by suggesting differences in worldviews characterise disciplinary research. 
This assumes that all nursing researchers share the same worldview and that 
researchers in other discipl~nes cannot access or participate in that worldview. 
Furthermore, such an assertion relegates the individual researcher to something of a 
predetermined position, a channel through which the 'nursing' wutin emerges. 
Certainly, paradigms can dominate a profession, and such paradigms may be 
expressed in the type of research generally conducted by that profession, but such 
pluralistic apartheid as expressed by Bums and Grove does not seem at home with 
the many interpretivist and constructivist approaches, where the investigator, the 
participants and the nature of their individual relationships define the outcome. To 
argue that a part is greater than and characterises the whole undermines the nature 
and value of such approaches. 
If it is so difficult to define nursing research, does it exist? Research in nursing is 
vibrant, but this verb phrase does not carry the meaning as the noun phrase 'nursing 
research'. The transdisciplinary nature of knowledge seems to make the title nursing 
research as presumptuous as the title medical research. Where health work is 
concerned, with disciplinary boundaries becoming increasingly vague, it would seem 
health research and research in nursing practice is possible, but that nursing research 
as a pure disciplinary project is not 
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Appendix 2: Cochrane Collaboration Wound Review Group Search 
Strategy for Specialised Register of Trials (Central) 
The editorial team of the Cochrane Wound Group assembles, maintains and 
administers a specialised register of controlled clinical trials at the editorial base. All 
trials in which allocation to an intervention has been described as random, or quasi- 
random are included in the register. Furthermore, all trials which are potentially 
random (i.e. the method of allocation is not stated as random but the trial design 
suggest that it may be so) are included. Thus potentially useful trials are not 
automatically excluded from the register. 
Electronic database searches: 
MEDLINE has been searched for randomised controlled trials (RCTs) and 
controlled clinical trials (CCTs) from 1966 to December 1997 using a mixture of free 
text terms and MeSH headings. From January 1998 CENTRAL is searched using a 
simplified search strategy including the following terms: 
WOUND INFECTION 
PILONIDAL CYST 
WOUNDS AND INJURIES 
WOUND HEALING 
LEG ULCER 
VARICOSE ULCER 
SKIN ULCER 
DECUBITUS 
MEDLINE ( O d  version) 1966-1997 
001 Decubitus ulcer/ or foot ulcer/ 
002 Leg ulcer/ or varicose ulcer/ 
003 Pilonidal cyst/ 
004 Skin ulcer/ 
005 Diabetic foot/ 
006 ((plantar or diabetic or heel or venous or stasis or arterial) adj ulcer$).tw 
007 ((decubitus or foot or diabetic or ischaemic or pressure) adj ulcer$).* 
008 ((pressure or bed) adj sore$).* 
009 ((pilonidal adj cyst) or (pilonidal adj sinus) or bedsore$).tw 
010 ((diabetic adj foot) or (cavity adj wound)).tw 
011 ((varicose or leg or skin) adj ulcer$).tw 
012 ((decubims or (chronic adj wound$)).* 
013 ((sinus adj wound$) or (cavity adj wound$)).tw 
014 or/l-l3 
015 debridement/ or biological dressings/ or bandages/ 
016 occlusive dressings/ or clothing/ or wound healing/ 
017 antibiotics/ or growth subsatnces/ or platelet derived growth factor/ 
018 fibroblast growth factor/ or electrical stimulation therapy&, ab, sh 
019 lasers/ or nutrition/ or surgery/ or surgery, plastic/ 
020 surgical flaps/ or skin transplantations/ or homeopathy/ or homeopathic/ 
021 acupuncture therapy/ or acupuncture/ or alternative medicine/ 
022 massage/ or iloprost/ or alginates/ 
023 zinc/ or zinc oxide/ or ointments/ or anti-infective agents/ 
024 dermatologic agents/ or colloids/ or cushions/ or wheelchairs/ 
025 beds/ or wound dressings/ 
026 (debridement or dressing$ or compress$ or cream$ or (growth adj factor$)).tw 
027 (pressure-relie$ or (recombinant adj protein$) or bandag$ or stocking$).tw 
028 (antibiotic$ or (electric adj therapy) or laser$ or nutrition$ or surg$).tw 
029 (homeopath$ or acupunture or massage or reflexology or ultrasound).tw 
030 (iloprost or alginate$ or zinc or paste$ or ointment$ or hydrocolloid$).tw 
031 ((compression adj therapy) or (compression adj bandag$) or wrap$).tw 
032 (bed$ or matress$ orwheelchair$ or (wheel adj chair) or cushion$).tw 
033 ((wound adj dressing$) or vitamin$ or bind$ or gauze$ or heals or healing).tw 
034 (diet or lotion$ or infect$ or reduc$ or (wound adj healing)).tw 
035 (treat$ or prevent$ or epidemiol$ or aetiol$ or etiol$ or therap$ or prevalence or 
incidence).~ 
036 or/15-35 
037 14 and 36 
038 random allocation/ or randomized controlled trials/ 
039 controlled clinical trials/ or clinical trials phase I/  or clinical trials phase IT/. 
clinical trials phase III/ or clinical trials phase rV/ 
040 clinical trials overviews/ 
041 single-blind method/ or double blind method/ 
042 publication bias/ or review/ or review, academic/ 
043 review tutorial/ or meta-analysis/ or systematic review/ 
044 ((random$ adj controlled adj trial$) or (prospective adj random$).tw 
045 ((random adj allocation) or random$ or (clinical adj trial$) or control$)).tw 
046 ((standard adj treatment) or cornpar$ or single-blind$ or double-blind$).tw 
047 (blind$ or placebo$ or systematic$ or (systematic adj review).tw 
048 (randomized controlled trial or clinical trial).pt or comparative study.sh 
049 or/38-48 
050 37 and 49 
051 limit 50 to human 
052 burns/ or wounds, gunshot/ or corned ucler/ or exp dentistry/ 
053 peptic ulcer/ or duodenal ulcer/ or stomach ulcer/ 
L L 
054 ((peptic adj ulcer) or (duodenal adj ulcer) or traum$).tw 
055 ((aortocaval adj fistula) or (arteriovenous adi fistula)).tw 
056 (bite adj wound$).tw 
057 or/52-56 
058 51 not 57 
EMBASE (Ovid uersion) 1780-1777 
CINAHL (Ovid version) 1980-1 777 
001 Pressure ulcer/ or foot ulcer/ or leg ulcer/ or skin ulcer/ 
002 Diabetic foot/ or diabetic neuropathies/ 
003 Diabetic angiopathies/ or diabetes mellitus.co 
004 Pilonidal cyst/ or surgical wound infection/ 
005 ((plantar or diabetic or heel or venous or stasis or arterial) adj ucler$).tw 
006 ((decubitus or foot or diabetic or ischaemic or pressure) adj ulcer$).tw 
007 ((pressure or bed) adj sore$).tw 
008 ((pilonidal adj cyst) or (cavity adj wound)).tw 
009 ((diabetic adj foot) or (cavity adj wound).tw 
010 ((varicose or leg or skin) adj ucler$).tw 
011 (decubitus or (chronic adj wound$)).tw 
012 ((sinus adj wound$) or cavity adj wound$)).nv 
013 or/l-12 
014 debridement/ or biological dressings/ or occlusive dressings/ 
015 @andages.ti,sh,ab,it and "Bandages and Dressingsn/) or 
016 compression garments/ or antibiotics/ 
017 electric stimulation/ or laser surgery/ or lasers.th/ nutrition care (Saba HHCC)/ 
or diet therapy/ or nutritive therapy (Iowa NIC)/ 
018 surgery, reconstmctive/ or surgery, plastic/ or surgical flaps/ 
019 surgical stapling/ or skin tranplantation/ or alternative therapies/ 
020 acuouncture/ or massage/ or zinc/ or ointments/ 
U .  
021 antiinfective agents, local/ antibiotics/ or dermatologic agents/ 
022 dermatolom nursing/ or colloids/ or beds and mattresses/ 
-. 
023 flotation beds/ or wheelchairs/ or positioning: wheelchair/ or positioning: 
therapy/ 
024 patient positioning/ or positioning/ or wound care/ or wound healing/ 
025 (debridement or dressing$ or compress$ or cream$).* 
026 ((growth adj factor$) or pressure relie$ or (recombinant a 4  protein$) or 
bandag$.tw 
027 (stocking$ or antibiotic$ or (electric adj therapy) or laser$ or nutrition$ or 
surg$) .tw 
028 (iloprost or alginate$ or zinc or paste$ or ointment$ or hydrocolloid$).tw 
029 ((compression adj therapy) or (compression adj bandag$) orwrap$).tw 
030 @ed$ or mattress$ or wheelchair$ or (wheel adj chair) or cushion$.tw 
031 ((wound adj dressing$) or vitamin$ or bind$ or gauze$ or heals or hea1ind.m 
032 (diet or lotion$ or infect$ or reduc$ or etiol$ or (wound adj healing)).* 
033 (treat$ or prevent$ or epidemiol$ or therap$ or prevalence or incidence).* 
034 "Bandages and DressingsN/ or skin transplantation/ or homepathy/ 
or ointments/ or "bed and mattresses" 
035 or /14-34 
036 13 and 35 
037 clinical trials/ or single-blind studies/ or double-blind studies/ 
038 control group/ or placebos/ or meta-analysis/ 
039 ((random$ adj clinical adj trial$) or (prospective adj random$)).tw 
040 ((random adj allocation) or random$ or controlled clinical trial$ or control).tw 
041 (comparison group$ or (standard adj treatment) or compar$).tw 
042 (single-blind$ or (single adj blind) or double-blind or (double adj blind)).* 
043 @lind$ or placebo$ or systematic or (systematic adj review)).tw 
044 (meta analysis or meta-analysis).tw or (trials or trial or prospective).tw 
045 (clinical trials).sh or (comparative studies).sh 
046 or/ 37-45 
047 36 and 46 
048 burns/ or wounds, or corned ulcer/ or exp dentistry/ 
049 peptic ulcer/ or duodenal ulcer/ 
050 ((peptic adj ulcer) or (duodenal adj ulcer) or trauma).* 
051 (@urn$ or (gunshot adj wound$) or (corned adj ulcer) or dentist$ 
or (bite adj wound$)).tw 
052 or/ 48-51 
053 47 not 52 
The following databases have also been searched from the earliest available date: 
IS1 Science Citation Index (on BIDS) 
BIOSIS (on Silver Platter) 
British Diabetic Association Database 
CISCOM (Complementary Medicine Database of the RCCM) 
Conference Proceedings (on BIDS) 
Database of Abstracts of Reviews of Effectiveness (DARE) 
Dissertation Abstracts 
Royal College of Nursing Database 
Journal handsearches 
Wound care specialty journals have been handsearched as follows: 
CARE - Science and Practice (later Journal of Tissue Viability) 1979-1990 
Journal of Tissue Viability 1991-present 
Decubitus 1987-1993 
Journal of Wound Care 1991-present 
Phlebology 1986-1995 
Conference Proceedings 
Proceedings of the 1st European Conference on Advances in Wound Management, 
1991 
Proceedings of the 2nd European Conference on Advances in Wound Management, 
1992 
Proceedings of the 3rd European Conference on Advances in Wound Management, 
1993 
Proceedings of the 4th European Conference on Advances in Wound Management, 
1994 
Proceedings of the 5th European Conference on Advances in Wound Management, 
1995 
Proceedings of the 6th European Conference on Advances in Wound Management, 
1996 
Proceedings of the 7th European Conference on Advances in Wound Management, 
1997 
3rd Annual Symposium on Advanced Wound Care, 1990 
4th Annual Symposium on Advanced Wound Care, 1991 
5th Annual Symposium on Advanced Wound Cate, 1992 
1996 Symposium on Advanced Wound Care &Medical Research Forum on Wound 
Repair 
Proceedings of: Going into the '90s: The Pharmacist and Wound Care,1992 
Proceedmgs of the Second Joint British/Swedish Angiology Meeting,l991 
Symposium on Venous Leg Ulcers, 1985 
Yd Annual Symposium on Advanced Wound Care, 1990 
4& Annual Symposium on Advanced Wound Care, 1991 
5& Annual Symposium on Advanced Wound Care, 1992 
Symposium on Venous Leg Ulcers, 1985 
znd Joint British/Swedish Angiology Meeting, 1991 
Going into the '90s: The Pharmacist and Wound Care, 1992 
1996 Symposium on Advanced Wound Care &Medical Research Forum on Wound 
Repair 
Unpublished Studies 
Several databases have been searched (up to December 1997) to attempt to identify 
unpublished studies. These include: 
CRIB (Current Research in Britain) 
DHSS Database 
SIGLE (Systematic Index. ofC;rey Literature in English) 
Healthstar 
UK National Research Regjster . , 
Smith & Nephew Wo~lnd Care Database 
Amed 
fixperts in wound c u r  znd pham~aceutical companies were contacted to enq~ire 
about unpublished, ongoing and recently pub!ished trials. Citations within obtairrcd 
reviews and papers were scru~nised to identifl additional studies. 
Appendix 3: Cochrane Collaboration Peripheral Vascular Diseases 
Review Group Search Strategy for Specialised Register of Trials 
(Central) 
The editorial team of the Cochrane Peripheral Vascular Diseases Group assembles, 
maintains and administers a specialised register of controlled clinical trials at the 
editorial base. The register presently contains 2754 references to relevant trials. 
Before a reference is entered onto the database, a photocopy is obtained, and codes 
assigned for characteristics of the trial such as the method of randomisation, disease 
being treated, and type of intervention. An additional database contains a further 
1500 uncoded references. 
All trials in which allocation to an intervention has been described as random, or 
.. .,. 
quasi-random are included in the register. Furthermore, all trials which are potentially 
random (i.e. the method of allocation is not stated as random but the trial design 
suggest that it may be so) are included. Thus potentially useful trials are not 
automatically excluded from the register. 
Electronic Database Searches 
MEDLINE (OVID uersion) 1966 t o  1999 (My) 
MEDLINE has been systematically searched using the following strategies (the first 
part developed by Carol Lefebvre): 
a) Identifying possible randomised controlled trials 
001 randomised controlled trial.pt. 
002 controlled clinical trial.pt. 
003 randomized controlled trials/ 
004 random allocation/ 
005 double-blind method/ 
006 single-blind method/ 
007 exp evaluation studies/ 
008 exp clinical trials/ 
009 clinical trial.pt. 
010 exp clinical trials/ or clin$ trial$.ti,ab,rw,sh. 
011 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
012 (sing18 or doubl$ or tripl$ or trebl$ or blind$).ti,ab,rw,sh. or  mask$.tw. 013 ey, 
placebos/ 
014 placebo$.tw. 
015 random$.tw. 
016 exp research design/ 
017 12 or 13 or 14 or 15 or 16 
018 11 or 17 
019 limit 18 to human 
b) combining a) with all of the following search strategies to identify possible RCTs 
in peripheral vascular diseases. The search for trials relating to peripheral vascular 
diseases has been divided into a number of strategies because of the large numbers of 
trials and the diversity of diseases. Each strategy can be tun separately to identify 
potential trials in a specific area (e.g. abdominal aortic aneurysm). 
articles relating to peripheral aneurysms 
020 peripheral aneurysm$.tw. 
021 (peripheral adj5 aneurysm$).tw. 
022 iliac aneurysm/ 
023 iliac aneurysm$.tw. 
024 femoral aneurysm$.tw. 
025 popliteal aneurysm$.tw. 
026 traumatic aneurysm$.tw. 
027 20 or 21 or 22 or 23 or 24 or 25 or 26 
028 27 and 19 
articles relating to arteriovenous fistulae 
029 arteriovenous fistula/ 
030 arteriovenous fistula$.tw. 
031 29 or 30 
032 31 and 19 
articles relating to polyarteritis nodosa 
033 polyarteritis nodosa/ 
034 polyarteritis nod0sa.m. 
035 33 or 34 
036 35 and 19 
articles relating to the prevention of pulmonary embolism 
037 exp pulmonary embolism/ 
038 pulmonary embolism.tw. 
039 37 or 38 
040 exp primary prevention/ 
041 prevention.tw. 
042 ptophylaxis.tw. 
043 40 or 41 or 42 
044 39 and 43 
045 44 and 19 
articles relating to peripheral arterial occlusive diseases 
046 peripheral vascular diseases/ 
047 vascular diseases/ 
048 arteriosclerosis obliterans/ 
049 atherosclerosis/ 
050 arterial occlusive diseases/ 
051 intermittent claudication/ 
052 (intermittent ad15 claudica$).tw. 
053 (arteriosclerosis adj5 obliterans).tw. 
054 (atherosclerosis adj5 obliterans).~. 
055 exp amputation/ 
056 (arnputat$).tw. 
057 (claudica$).tw. 
058 (peripheral adj5 arteri$).tw. 
059 (peripheral adj5 occlu$).tw. 
060 (peripheral adj5 vascular).tw. 
061 (limb adj5 ischaem$).tw. 
062 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 
or 60 or 61 
063 62 or (peripheral adj5 disease$).tw. 
064 63 and 19 
articles relating to abdominal aortic aneurysms 
065 aortic aneurysm, abdominal/ 
066 aortic rupture/ 
067 aorta, abdominal/ 
068 (abdominal adj5 aneurysm$).tw. 
069 aneurysm, ruptured/ 
070 (aortic adj5 aneurysm$).tw. 
071 (abdominal adj5 dilatation$).tw. 
072 (thoracoabdominal adj5 aneurysm).tw. 
073 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 
074 73 and 19 
articles relating to vasospastic disorders 
075 raynaudls disease/ 
076 (raynaud$).tw. 
077 (raynaud's adj5 disease$).tw. 
078 (raynaudls adj5 phenomen$).tw. 
079 (digital adj5 vasospasm).tw. 
080 75 or 76 or 77 or 78 or 79 
081 80 and 19 
articles relating to chronic venous insufficiency and varicose veins 
082 varicose veins/ 
083 venous insufficiency/ 
084 phlebography/ 
085 (varicose adj5 vein$).tw. 
086 phlebography.tw. 
087 (venous a45 insufficiency).tw. 
088 (chronic venous insufficienq).tw. 
089 82 or 83 or 84 or 85 or 86 or 87 or 88 
090 89 and 19 
articles relating to vascular surgery 
091 vascular surgical procedures/ 
092 vascular surg$.tw. 
093 exp angioplasty/ 
094 femoral artery/ 
095 popliteal artery/ 
096 femoro?popliteal.tw. 
097 94 or 95 or 96 
098 graft.tsv. 
099 97 and 98 
100 revascular$.tw. 
101 bypass.tw. 
102 dista1.t~. 
103 femoro$.tw. 
104 1010r102 orl03.ti,ab,rw,sh. 
105 saphenous vein/ 
106 reverse.tw. 
107 105 and 106 
108 popliteal.tw. 
109 101 and 102 and103 
110 91 or 92 or 93 or 94 or 95 or 96 or 99 or 100 or 104 or 107 or 108 or 109 
111 110 and 19 
articles relating to.arteria1 and mixed ulcers, of the foot and leg 
112 leg ulcer/ 
113 foot ulcer/ 
l14 (arterial ad15 ulcer$).tw. 
115 (leg ad15 ulcer$).m. 
116 (foot adj5 ulcer$).tw. 
117 (isch?emi$ adj5 ulcer$).tw. 
118 112 or 113 or 114 or 115 or 116 or 117 119 118 and 19 
articles relating to thromboembolism 
120 thromboembolism/ 
121 thrombophlebitiis/ 
122 exp heparin, low-molecular-weight/ 
123 femoral vein/ 
124 popliteal vein/ 
125 (venous adj5 thrombQ.tw. 
126 DVT.m. 
127 thromboembolism.tw. 
128 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 129 128 and 19 
articles relating to all PVD scope topics 
EMBASE (OWD version) 1980 t o  1999 (March) 
Mrs Hazel Dunn and Prof Jos Iaeijnen have searched EMBASE (OVID version) 
from 1980-1997. Dr Carol Forbes has searched EMBASE (OVlD version) from Jan 
to Nov 1998. The strategies used were: 
a) Identifying possible randomised controlled trials 
001 randomization/ 
002 controlled study/ 
003 single blind procedure/ 
004 placebo/ 
005 double blind procedure/ 
006 clinical mal/ 
007 crossover procedure/ 
008 p1acebo.w. 
009 blind$  fashion.^. 
010 random$.tw. 
011 clinical trial?.tw. 
012 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 
013 limit 12 to human 
b) combining a) with all of the following search strategies to identify possible RCTs 
in peripheral vascular diseases. The search for trials relating to peripheral vascular 
diseases has been divided into a number of strategies because of the large numbers of 
trials and the diversity of diseases. Each strategy can be run separately to identify 
potential mals in a specific area (e.g. abdominal aortic aneurysm). 
articles relating to peripheral arterial occlusive diseases 
014 claudica$.tw. 
015 (peri$ adj7 occlusi$).tw. 
016 (occlusi$ disease and lower extremity).tw. 
017 (leg? adj7 isch?em$).tw. 
018 (limb? ad17 isch?em$).tw. 
019 (occlusive adj7 arteriosclerosis).tw. 
020 intermittent claudication/ 
021 claudication/ 
022 blood vessel occlusion/ 
023 leg ischemia/ 
024 limb ischemia/ 
025 femoral artery/ 
026 popliteal artery/ 
027 iliac artery/ 
028 superficial femoral artery/ 
029 internal iliac artery/ 
030 artery occlusion/ 
031 occlusi$.tw. 
032 25 or 26 or 27 or 28 or 29 
033 30 or 31 
034 32 and 33 
035 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 34 
036 35 and 13 
articles relating to thromboembolism and prevention or pulmonary embolism 
037 thromboembolism/ 
038 thrombophlebitis/ 
039 (venous adj7 thromb$).tw. 
040 thromboembolism.tw. 
041 (pulmonary adj5 embolism).tw. 
042 prevention/ 
043 prophylaxis/ 
044 prevention.tw. 
045 propliylaxts.tw. 
046 42 or 43 or 44 or 45 
047 41 and 46 
048 embolism prevention/ 
049 thrombosis prevention/ 
050 37 or 38 or 39 or 40 or 47 or 48 or 49 
051 50 and 13 
articles relating to abdominal aortic aneurysms 
052 abdominal aorta aneurysm/ 
053 aorta rupture/ 
054 abdominal aorta/ 
055 aneurysm rupture/ 
056 (abdominal ad15 dilatadon).tw. 
057 (aortic adj5 aneurysm).tw. 
058 (abdominal adj5 aneurysm).tw. 
059 (thoracoabdominal a45 aneurysm).tw. 
060 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 
061 60 and 13 
articles relating to vasospastic disorders 
062 raynaud phenomenon/ 
063 raynaud$.tw. 
064 (raynaud? adj5 disease?).tw. 
065 (raynaud? adj5 phenomen$).tw. 
066 (digital adj5 vasospasm$).tw. 
067 62 or 63 or 64 or 65 or 66 
068 67 and 13 
articles relating to mixed and arterial ulcers, of the foot and leg 
069 foot ulcer/ 
070 leg ulcer/ 
071 plantar ulcer/ 
072 trophic ulcer/ 
073 (chronic adj5 ulcer?).tw. 
074 (isch?em$ adj5 ulcer?).tw. 
075 (arterial ad15 ulcer?).tw. 
076 foot ulcer$.tw. 
077 leg ulcer$.tw. 
078 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 
079 78 and 13 
articles relating to chronic venous insufficiency and varicose veins 
080 exp vein insufficiency/ 
081 leg phlebography/ 
082 leg varicosis/ 
083 (varicose adj 5 vein$).tw. 
084 p11lebography.tw. 
085 (venous adj5 insufficiency).tw. 
086 80 or 81 or 82 or 83 or 84 or 85 
087 86 and 13 
articles relating to arteriovenous fistulae 
088 arteriovenous fistula/ 
089 arteriovenous fistula$.*. 
090 88 or 89 
091 90 and 13 
articles relating to polyarteritis nodosa 
092 polyarteritis nodosa/ 
093 polyarteritis n o d o s a . ~ .  
094 92 or 93 
095 94 and 13 
articles relating to vascular surgery 
096 vascular surgery/ 
097 vascular surg$.tw. 
098 angioplasty/ 
099 femorofemoral bypass/ 
100 femoropopllteal bypass/ 
101 saphenous vein graft/ 
102 femoral artery/ 
103 popliteal artery/ 
104 femoro?popliteal.tw. 
105 102 or 103 or 104 
106  graft.^. 
107 105 and 106 
108 bypass.tw. 
109 dista1.m. 
110 femoro$.tw. 
111 108and109and110 
112 96 or 97 or 98 or 99 or 100 or 101 or 107 or 111 
113 112 and 13 
articles relating to peripheral aneurysms 
114 peripheral aneurysm$.tw. 
115 (peripheral ad15 aneurysm$).tw. 
116 (femoral adj5 aneurysm$).tw. 
117 (popliteal adj5 aneurysm$).*. 
118 (iliac adj5 aneurysm$).*. 
119 114 or 115 or 116 or 117 or 118 
120 119 and 13 
articles relating to all PVD scope topics 
Joumal Handsearches 
The following 38 core journals relating to peripheral vascular diseases are presently 
being handsearched, or have been handsearched up until last issue. Up to date 
information on journal handsearching can be found at U r n  www.cochrane.org. 
Angiology (1950-1997 - ongoing) 
Annals of Vascular Surgery (1986-1998 - ongoing) 
Arteriosclerosis (1981-1990) 
Arteriosclerosis and Thrombosis (1991-1995) 
Arteriosclerosis, Thrombosis and Vascular Biology (1995) 
Atherosclerosis (1970-1996) 
Circulation (1980-1988) 
Clinical and Applied Thrombosis/Haemostasis (1995.1998 - ongoing) 
Clinical Haernorheology (1981-1996) 
Critical Ischaemia (1990-1995) 
European Journal of Vascular and Endovascular Surgery (1994-1998 - ongoing) 
Haemostasis (1972-1996 - ongoing) 
International Angiology (1982.1998 - ongoing) 
International Journal of Angiology (1992-1996 - ongoing) 
Journal ofAtherosclerosis Research (1961-1969) 
Journal of Smoking Related Disorders (1991-1995) 
Journal of Thrombosis and Thrombolysis (1994.1996 - ongoing) 
Journal of Vascular and Interventional Radiology (1990-1998 - ongoing) 
Joumal of Vascular Investigation (1995-1997) 
Journal of Vascular Medicine and Biology (1989-1994) 
Journal of Vascular Nursing (1991-1998 - ongoing) 
Journal of Vascular Surgery (198.4-1998 - ongoing) 
Microvascular Research (1968-1996) 
Perfusion (1988-1994) 
Phlebology (1986-1998 - ongoing) 
Prostaglandins and Medicine (1978-1981) 
Prostaglandins Leukotrienes and Medicine (1982-1987) 
Prostaglandins Leukotrienes and Essential Fatty Acids (1988-1995) 
Regional Anesthesia (1980-1996) 
Seminars in Thrombosis and Haemostasis (1974-1998) 
Seminars in Vascular Surgery (1988-1998 - ongoing) 
Thrombosis et Diathesis Haemorrhagica (1957-1977) 
Thrombosis and Haemostasis (1978-1998 - ongoing) 
Thrombosis Research (1972- 1997 - ongoing) 
Vascular Diseases (1964-1968) 
Vascular Medicine (1996-1997) 
Vascular Surgery (1967-1998 - ongoing) 
VASA (1985-1997) 
Conference Proceedings 
The following conference proceedings have been searched, and are displayed 
according to the year in which the conference was held: 
Venous Forum of the Royal Society of Medicine, Weetwood Hall, Leeds, UI<; 16 
April 1999. Abstracts 
A Symposium of the Venous Forum of the Royal Society of Medicine, Edinburgh, 
UI<; 22-23 October 1998. Epidemiology, Management & Delivery of Care for 
Venous Disease - Short Papers, 1998 
The Vascular Surgical Society of Great Britain & Ireland. 31st Annual Conference, 
26-28 November 1997. The Royal Lancaster Hotel, London, UK 
European Society for Vascular Surgery. XI Annual Meeting. Lisbon, Portugal, 17-20 
September, 1997 
Fourth International Congress on Essential Fatty Acids & Eicosanoids. Edinburgh, 
U y  July 20-24, 1997 (PVD articles only) 
XVIth Congress of the International Society on Thrombosis and Haemostasis, 
Florence, Italy; 6-12 June 1997. Thrombosis and Haemostasis Supplement, June 
1997: 1-844 
Atherothrombosis and Peripheral Arterial Disease. Boston, USA, June 1, 1997 (PVD 
articles only) 
Cardiovascular Disease Prevention 111. London, February 1997 
Proceedings of the Second Pacific Vascular Symposium: Advances in Venous 
Disease. I h u e l a ,  Hawaii, November 1996 
Proceedings of the 30th Annual Conference of the Vascular Society of Great Britain 
and Ireland. Bournemouth International Centre, 20-22 November 1996 
European Society for Vascular Surgery 10th Annual Meeting, 12-15 September 1996, 
Venice, Italy 
International Union of Angiology European Chapter's Congress. Budapest, Hungary, 
May 19-20, 1996 
New Aspects of Haemophll~a Treatment. Proceedings of the 3rd symposium. 
Copenhagen, Denmark, September 21-23, 1995. Haemostas~s 1996;26 Suppl 1:l-l66 
Union Internationale de Phlebologie XI1 World Congress, 3 - 5 September 1995, 
London, UI<. Phlebology '95 1995; 1 and 2 
XVth Congress of the International Society on Thrombosis and Haemostasis. 
Jetusalem, Israel, June 11-16, 1995. Abstracts.Thrombosis & Haemostasis 1995 June; 
73(6):899-l534 
Proceedings of the 64th European Atherosclerosis Society Congress. Utrecht, 10-13 
June 1995. Atherosclerosis 1995 December; 118 SuppkS1-l49 
64th European Atherosclerosis Society Congress. Utrecht, 10-13 June 1995. 
Abstracts. Atherosclerosis 1995 June; 115 Suppl:Sl-l49 
International Union of Angiology. London, April, 1995. International Angiology 
1995; part 1, Suppl 1 
Proceedings of the XI1 World Congress of the International Union of Phlebology-- 
parallel session entitled medical and socioeconomic impact of venolymphatic disease: 
benefit of daflon 500 mg. London, 1995. Angiology 1997 January; 48(1):21-98 
Xth International Symposium on Atherosclerosis. Montreal, 9-14 October 1994. 
Abstracts. Atherosclerosis 1994 Sep 15;109(1-2):l-354 
European Society for Vascular Surgery 8th Annual Meeting, 3-6 September 1994, 
Berlin, Germany 
5th Mediterranean Congress of Angiology and Vascular Surgery. Ajaccio, Corsica, 
June 20-23, 1994. Abstracts. International Angiology 1994 June; 13(2 Suppl 1):l-89 
13th International Congress on Thrombosis, 10th National SETH Congress, 6th 
Nursing Workshop. Bilbao, Spain, June 6-10, 1994. Abstracts. Haemostasis 1994;24 
Suppl 1:l-410 
"EUROCHAP" -94. Angiology. IIIrd meeting of British-Swedish Angiology 
Societies. Lund, Sweden, May 15-19, 1994. Abstracts. International Angiology 1994 
March; 13(1 Suppl 1):l-l10 
4th International Workshop on Lipid Metabolism. Dijon, France, 15-16 April 1994. 
Proceedings and absa-acts. Atherosclerosis 1994 Oct;110 SuppkSl-106 
International Conference on Vascular Diseases of Lower Limbs. Bari, Italy, 
November 19-20,1993. Abstracts. International Angiology 1993 Sep;12(3 Suppl 1):l- 
85 
European Society for Vascular Surgery 7th Annual Meeting, 22-24 September 1993, 
Barcelona, Spain 
British Hyperlipidaemia Association; 7th Scientific & Annual General Meeting. 
Newcastle-upon-Tyne, UK July 8-10, 1993 (PVD articles only) 
XIVth International Congress on Thrombosis and Haemostasis, 1993 State of the 
Art. New York, New York, July 1993. Papers. Thrombosis & Haemostasis 1993 Jul 
1;70(1):1-232 
XIVth Congress of the International Society on Thrombosis and Haemostasis. New 
York, New York, USA. July 4-9, 1993. Abstracts. Thrombosis & Haemostasis 1993 
Jun 30;69(6):539-l455 
The proceedings of the Straub Pacific Health Foundation; Hawaii, June 12-14,1993 
2nd International Joint Workshop on Atherosclerosis, Peripheral Arterial Disease, 
New Trends in Cardiovascular Therapy. Proceedings. Monte Carlo, January 28-30, 
1993. International Angiology 1993 Dec;12(4):326-86 
International Congress VI: Endovascular Interventions--Tomorrow's Technology 
Today. Scottsdale, Arizona, January 27-31, 1993. Abstracts. Angiology 1993 January; 
44(1 Supp1):l-30 
12th National Congress of the Italian Society for the Study of Haemostasis and 
Thrombosis in collaboration with the Spanish Group of Haemostasis and 
Thrombosis. P m a ,  Italy, September 27 - October 1 1992. Thrombosis Research 
1993;70 Suppl 1 
European Society for Vascular Surgery 6th Annual Meeting, 2-4 September 1992, 
Athens, Greece. 
Proceedings of the 3rd Novo Nordisk International Symposium on Thrombotic 
Disorders. Copenhagen, Denmark September 30-October 1, 1992. Haemostasis 
1993 Mar;23 Suppl 1:l-228 
Union Internationale de Phlebologie XI World Congress, 30 August - 4 September 
1992, Montreal, Canada. Phlebology 92 1992; 1 and 2 
Hemostasis in Liver Transplantation. Proceedings of a workshop. Berlin, Germany, 
August 1992. Seminars in Thrombosis & Hemostasis 1993;19(3):183-314 
Abstracts of the 12th International Congress on Thrombosis. Florence, Italy, May 
18-23,1992. Thrombosis Research 1992;65 Suppl 1 
Strategies in endovascular interventions. Proceedings of the International Congress 
V--Part 2. Scottsdale, Arizona, February 12-16, l392. Abstracts. Angiology 'i992 
Mar;43(3 Pt 2):253-79 
At the Crossroads of Venous Insufficiency and Hemorrhoidal Disease: Daflon 500 
mg. Proceedings of a symposium. Vienna, Austria, January 31, 1992. Angiology 1994 
Jun;45(6 Pt 2):493-584 
Vascular Symposium:'Angioplasty, Thrombolysis & Angioscopy - A minimally 
invasive approach to arterial disease'. Department of Surgery, University of 
Edinburgh, UI(, November 8, 1991 
European Society for Vascular Surgery 5th Annual Meeting, 25-27 September 1991, 
Warsaw, Poland 
XIIIth Congress of the International Society on Thrombosis and Haemostasis. 
Amsterdam, the Netherlands, 30 June - 6 July 1991. Abstracts. Thrombosis & 
Haemostasis 1991 June 5;65(6):645-l366 
Low, Molecular Weight Heparins and Related Polysaccharides. Proceedings of an 
international symposium. Munich, Germany, June 27-28, 1991. Issue dedicated to 
Gunther Blumel. Seminars in Thrombosis & Hemostasis 1993;19 Suppl 1:l-247 
Development of non-heparin glycosaminoglycans as therapeutic agents: 11. A 
symposium. Chicago. Seminars in Thrombosis & Hemostasis 1991;17 Suppl 2137- 
245 
Papers from the Per~pheral Vascular Surgical Society 1991 meeting. Annals of 
Vascular Surgery 1992 January; 6(1):1-98 
9th National Conference on Thrombosis and Hemostasis. Dallas, Texas, November 
1990. Abstracts. Arteriosclerosis 1990 September-October; 10(5):887a-957a 
63rd Scientific Sessions of the American Heart Association: Nutrition. Dallas, Texas, 
November 1990. Abstracts. Arteriosclerosis 1990 September-October; 10(5):872a- 
886a 
44th Annual Meeting. Council on Arteriosclerosis. Dallas, Texas, November 199G. 
Abstracts. Arteriosclerosis 1990 Sep-Oct;10(5):751a-871a 
European Society for Vascular Surgery 4th Annual Meeting, 20-21 September 1990, 
Rome, Italy 
Thrombosis and fibrinolysis: current clinical and therapeutic aspects. Chicago 
Satellite Symposia of the Xth International Congress of Fibrinolysis. Chicago, August 
2-3,1990. Seminars in Thrombosis & Hemostasis 1991 October; 17(4):317-476 
Cell biology of fibrinolysis. Tenth International Congress on Fibrinolysis. August 
1990. Seminars in Thrombosis & Hemostasis 1991 July; 17(3):159-312 
Fifteenth annual meeting of the Peripheral Vascular Surgery Society. June 2, 1990, 
Los Angeles, California.Annals of Vascular Surgery 1991 Mar;5(2):105-95 
Heparin-present and future. Proceedings of a symposium. Florence, March 28-31, 
1990. Haemostasis 1990;20 Suppl 1:4-223 
Papers from the French Vascular Surgery Society 1990 meeting. Annals of Vascular 
Surgery 1991 January; 5(1):1-65 
10th Congres Modial Union Intemationale de Phlebologie. Strasbourg, France, 25-29 
August 1989 
XIIth Congress of the International Society on Thrombosis and Haemostasis. 
Tokyo, Japan, 19-25 August 1989. Abstracts. Thrombosis & Haemostasis 1989 
August 19;62(1):1-647 
Clinical significance of fibr~nolysis. XIIth congress of the International Society on 
Thrombosis and Haemostasis. August 1989. Proceedings. Seminars in Thrombosis & 
Hemostasis 1990 July; 16(3):203-73 
New aspects on hirudin. Proceedings of the 1st International Symposium on 
Hirudin. Frankfurt, June 23-24, 1989. Haemostasis 1991;21 Suppl 1:l-l71 
Papers from the French Society for Vascular Surgery--1989 meeting. Annals of 
Vascular Surgery 1990 March; 4(2):105-70 
8th National Conference on Thrombosis and Hemostasis. Washington, D. C., 
November 1988. Abstracts. Arteriosclerosis 1988 September-October; 8(5):648a- 
736a 
42nd annual meeting, Council on Arteriosclerosis, American Society for the Study of 
Arteriosclerosis. Washington, D.C., November 1988. Abstracts. Arteriosclerosis 1988 
September-October; 8(5):549a-647a 
Management and clinical use of intravenous nicarpidine. Presented at the 35th annual 
meeting of the American College of Angiology. Orlando, Florida, October, 1988. 
Proceedings. Angiology 1990 November; 41(11 Pt 2):977-l022 
European Society for Vascular Surgery 2nd Annual Meeting, 14-16 September 1988, 
Rotterdam, The Netherlands 
New pharmacological and clinical properties of the venoactive agent: Venoruton 
(Paroven). Studies presented at the 1st Mediterranean Congress of Angiology. Corfu, 
Greece, May 29 to June 3, 1988. Abstracts. International Angiology 1988 October- 
December; 7(4 Supp1):l-l6 
Proceedings of a symposium on Fluxum (low molecular weight heparin): a new 
prophylactic and therapeutic approach to thromboembolic diseases. Held during the 
1st Mediterranean Congress of Angiology. Corfu, Greece, June 2, 1988. International 
Angiology 1988 July-September; 7(3 Supp1):l-47 
Lymphatic system and microcirculation. Proceedings of the Third Intemational 
Symposium on Daflon 500 held during the First Mediterranean Congress of 
Angiology. Corfu, Greece, May 31, 1988. International Angiology 1989 October- 
December; 8(4 Supp1):l-75 
41st annual meeting, Council on Arteriosclerosis, American Society for the Study of 
Arteriosclerosis. Anaheim, California, November 1987. Abstracts. Arteriosclerosis 
1987 September-October; 7(5):491a-563a 
Hypertriglyceridemia, arteriosclerosis, and thrombosis: I. September 21-23, 1987, 
Washington, D.C. Proceedings of a workshop. Seminars in Thrombosis & 
Hemostasis 1988 April; 14(2):137-221 
Hypertriglyceridemia, arteriosclerosis, and thrombosis: 11. September 21-23, 1987, 
Washington, D.C. Proceedings. Seminars in Thrombosis & Hemostasis 1988 July; 
14(3):227-92 
International Symposium on Familial Hypercholesterolemia. Oslo, Norway, August 
28-29,1987. Proceedings. Arteriosclerosis 1989 January-February; 9(1 Supp1):Il-l68 
Abstracts of a Satallite Symposia. XIth Intemational Congress on Thrombosis and 
Haemostasis, 11 July 1987; Brussels, Belgium. Thrombosis Research Supplement 
VII, 1987 (PVD articles only) 
XIth International Congress on Thrombosis and Haemostasis. Bmssels, Belgium, 6- 
10 July, 1987. Abstracts. Thrombosis & Haemostasis 1987 July 6;58(1):1-670 
Abstracts of a symposium on "Factor VIII/von Willebrand Factor, Platelet 
Formation, and Function in Health and Disease: A Tribute to Dr. Marion I. 
Barnhart". Detroit, Michigan, November 21-22, 1986. Seminars in Thrombosis & 
Hemostasis 1987 April; 13(2):228-37 
Recent advances and new developments in hemostaseology. 4th Congress of the 
Society on Thrombosis and Haemostasis (GTH). October 12-16, 1986, Dusseldorf. 
Abstracts. Haemostasis 1986;16 Suppl 51.148 
Low-molecular-weight heparins. Pharmacology, in vitro and ex vivo effects and 
clinical results. 4th Congress on Thrombosis and Haemostasis Research. Dusseldorf, 
October 12-16, 1986. Proceedings. Haemostasis 1988;18 Suppl3:l-88 
32nd Annual Meeting of the International Committee on Thrombosis and 
Haemostatis, and 9th Congress of the Mediterranean League against 
Thromboembolic Diseases, Jerusalem, Israel; 1-6 June 1986. Thrombosis Research 
Supplement VI, 1986 (PVD articles only) 
Xth Intemational Congress on Thrombosis and Haemostasis. July 15-19, 1985. 
Abstracts. Thrombosis & Haemostasis 1985 July 14;54(1):1-372 
Fragmin. Satellite symposium to the 10th congress of the International Society of 
Thrombosis and Hemostasis. San Diego, July 1985. Haemostasis 1986;16 Suppl 2:l- 
71 
Low molecular weight heparin and its clinical use. International Enoxaparin 
symposium. San Diego, July 1985. Haemostasis 1986;16(2):69-l88 
International Conference on Tl~rombolysis. Paris, March 15, 1985. Haemostasis 
1986;16 Suppl 3:l-152 
Clinical relevance of hemostaseological findings. Abstracts. International symposium 
and 29th anniversary of the DAB/GTH Saarbrucken, February 20-23, 1985. 
Haemostasis 1985;15(1):1-86 
The use of beta-adrenergic blockers in the treatment of angina and hypertension. A 
clinical symposium. 31st annual meeting, American College of Angiology and 21st 
annual meeting, International College of Angiology. San Antonio, Texas, November 
6,1984. Angiology 1986 Mar;37(3 Pt  2):215-62 
The clinical scope of disopyramide. A clinical symposium. San Antonio, Texas, 
November 5, 1984. Proceedings. Angiology 1987 Feb;38(2 Pt 2):165-204 
Third meeting of the Working Group on Peripheral Circulation. Palermo, September 
6-8, 1984. International Angiology 1985 Oct-Dec;4(4 Supp1):l-l97 
Proceedings of the defibrotide symposium. 8th International Congress on 
Thrombosis. Istanbul, June 4-7, 1984. Haemostasis 1986;16 Suppl 1:l-68 
7th International Congress on Fibrinolysis. Venezia, March 27-30, 1984. Abstracts. 
Haemostasis 1984;14(1):1-156 
Proceedings of a Symposium , 27-29 September, 1982; Toronto, Canada. 
Thrombosis Research Supplement IV; Pharmakinetic and Pharmacodynarnic 
Approach to Antithrombotic Therapy, 1983 (PVD articles only) 
Symposium of the XI1 European Conference on Microcirculation, 7 September 
1982; Jerusalem, Israel. Thrombosis Research Supplement V; The Endothelial Fibrin 
Lining, 1983 (PVD articles only) 
Seventh International Congress on Thrombosis. Valencia (Spain), October 13-16, 
1982. Abstracts. Haemostasis 1982;12(1-2):1-237 
Sixth International Congress on Fibrinolysis. Lausanne, July 20-23, 1982. Abstracts. 
Haemostasis 1982;ll Supp1:l-l07 
35th annual meeting: Council on Arteriosclerosis, American Society for the Study of 
Arteriosclerosis, Dallas, Texas, November 1981. Abstracts. Arteriosclerosis 1981 
September-October; 1(5):353a-404a 
The haemophiliac in the eighties. Workshop 111: National haemophilia societies and 
WFH. Haemostasis 1981;lO Suppl 130-l08 
The haemophiliac in the eighties. Workshop 11: Mobilizing suppoa for haemophilia 
care. Haemostasis 1981;lO Suppl 1:51-79 
34th Annual Meeting. American Society for the Study of Arteriosclerosis. Miami 
Beach, Florida, November 1980. Abstracts. Arteriosclerosis 1981 Jan-Feb;1(1):52-l06 
The haemophiliac in the eighties. Proceedings of the 1st International Haemophilia 
Conference. 14th World Federation of Hemophilia General Assembly Bonn, 
October 3-7, 1980. Haemostasis 1981;10 Suppl 1:l-308 
VIIth International Congress on Thrombosis and Haemostasis, London 15--20 July 
1979. Abstracts. Thrombosis & Haemostasis 1979 July 16;42(1):6-533 
Hemorheology and Thrombosis. Proceedings of the United States-Japan Cooperative 
Seminar, Kobe, Japan, April 28 - May 2; 1975. Thrombosis Research 1975;8 Suppl2 
Efforts To Identify Unpublished Studies 
Members of the Group are aware of the importance of identifying unpublished trials. 
Reviewers are provided with standard forms which can be sent to those performing 
trials to obtain details of relevant investigations. Some drug companies, and 
companies producing diagnostic equipment (e.g. duplex scanners) have also been 
contacted, and asked whether they are aware of ongoing trials. At the present time it 
is the responsibility of individual reviewers to contact the drug companies 
manufacturing the medicines under review. 
An offer to supply trial data concerning Ginkgo biloba supplements has been 
received from Schwabe, and will be followed up shortly. 
Other Sources Searched 
An International Venous Taskforce handsearched several journals (not strictly 
according to the Cochrane criteria) and compiled the results into a series of booklets. 
These have been handsearched by members of the editorial team. 
Mrs Hazel Dunn, has partially searched the ad referendum database published by 
Info-Med U[<; the Cardiovascular Medicine section has been completed to October 
1996, and the Rheumatology section for 1996. 
Appendix 4: Inclusion/Exclusion Coding Sheet 
Study: 
Include/Exclude (circle one) 
Inclusion criteria 
Allocation described as 
randomised? 
Venous ulceration only or 
separate a.rm of factorial trial? 
Diagnosis derived from 
clinical signs/symptoms as a 
minimum? 
Intervention=Pentox + 
compression vs placebo + 
compression 
Primary outcome is objective 
outcome assessment? 
Reason for exclusion: 
Appendix 5: Data Extraction Coding Form 
Authors 
Title 
Joumal/year/date/pages 
Study location 
Study setting 
Wound type 
How aetiology 
Design 
determined 
Outcome l 1 
Allocation method 
Quality of Allocation 
Blinding. 
How assessed 
Outcome 2 
How assessed 
Outcome 3 
Clear Unclear Inadequate 
I How assessed l l 
Number of treatment 
a r m s  
Numbers in each arm 
Inclusion criteria I 
S ex 
M e a n  rh~ratinn nf 111rer I 
Mean ulcer size 
ABPI (resting?) 
BM1 
Hx of DVT 
Comorbidities 
-~~ 
(Other 
95 
-. 
Side effects 
Outcome 2 
Outcome 3 
Numbers (total) 
Reason (n=) 
Reason (n=) 
Reason (n=) 
Reason (n=) 
L L A <  
(specify) 
I1 = 12 = I3 = 
(specify) 
T1 = 12 = I3 = 
1 A priori sample size 
calculation? 
Sponsorship? 
Intention to treat 
analysis? 
Any impt outcome 
measures omitted? 
Any other comments? 
Appendix 6: Evidence Tables 
Barbmno (1992) RCT; 2 arm parallel group; 12 participants treated for 1 
double blind; matching week as inpahent and 8 weeks 
placebo as outpahents. 
Inclusion criteria: ulcer>2 
years duration, ulcer resistant 
to conventional therapy, AB1 
> 0.8. Exclusion criteria. 
chronic peripheral obstructive 
arterial disease; diabetes; 
disorders of urculatory 
system. Mean age: 1. 63.16 
years, 2. 64.83 years. Mean 
ulcer duration: 1.26.83 
months, 2. 26.33 months. 
Mean ulcer size: 1. 14.12 sq cm 
,2.14.47 sq cm. Mean ABI: 1. 
0.84,2. 0.85. 
Group 1: (n=6) pentoxi@lliue Complete healing: 1. 4/6 
1200mgin 3 divided doses (66%), 2. 1/6 (16.67%). Mean 
daily, plus 2 layer compression reduction in ulcer size 
bandaging. @ercent): 1. 90.6%, 2. 58.1%. 
Group 2: (n=6) placebo plus 2 Side effects: 1. 2/6 (33.3%), 2. 
layer compression bandaging. 1/6 (16.67%). Nil withdrawals. 
Treatment duration: 7 days 
inpatient, 60 days outpatient. 
Each participant tested for 
responslveness to treatment 
prior to randomisation and 
then underwent washout 
period for 2 weeks. During 
hospitalisation, participants 
received 200mg intravenous 
pentoxifyhe twice daily in 
addition to oral dose (1U)Omg) 
or matching placebo. 
Colgan, et al. RCT; 2 arm parallel group; 80 participants in 4 centres; 
(1990) double blind; matching outpatient clinics. Indus~on 
placebo criteria: at least 2 months 
standard treatment with no 
improvement, AB1 > 0.8, ulcer 
clinically venous, no 
contraindication to 
pentoxifyhe. Exclusion 
criteria: not reported. Mean 
age: group 1. 71, group 2. 70.2. 
Mean duration of ulcer: 1. 
6mon, 2. 9mon. Mean ulcer 
size: 1. 5.2sq cm, 2. 4.7 sq cm. 
Mean ABI: 1. 1.05,2. 1.06 . 
Group 1: ( ~ 3 8 )  pentoxifylline 
1200mgin 3 divided doses 
daily, plus 2 layer compression 
bandagmg. Group 2: (n=42) 
placebo, plus 2 layer 
compression banda& 
Treatment duration: until 
reference ulcer healed or 24 
weeks 
Number healed at 24 weeks: 1. Complete healing = healing of 
23/38 (60.5%), 2. 12/42 reference ulcer 
(28.6%). Side effects: 1. 17/38 
(44.7%), 2. 14/42 (33.3%). 
Withdrawals: 1. 3/38,2. 9/42. 
Reasons: oedema & 
depression, dyspepsia & 
diarrhoea, vomiting, skin rash, 
dizziness & diarrhoea, cellulitis 
&pain, headache &nausea, 
misdiagnosed pemphigoid, 
poor compliance. 
Dale, et al. (1999) Factorial RCT, sequential 200 participants in two 
sealed envelop; double blind; centres; outpatient cenaes. 
matching placebo Inclusion criteria: Age > 18; 
duration > 2mon; nlcer size > 
1 diameter; pure venous 
aetiologg. Exclusion criteria: 
M1 in past 3mon; 
haemorrhage in past 8 weeks; 
hypersensitivity to xanthines, 
p e n t o x i w e ,  and ddnks 
containing cola or caffeine; 
systemic treatment with 
coticosteroids, cytotoxics, 
naftidrohryl, oxymtin, 
anticoagulents, fibrinolytics or 
experimental drugs with last 
3mon; lumbar sympathectomy 
within last 3 weeks; presence 
of right heart fdure; sreum 
creatinine > 180 
micromol/litre; heaptic 
insufficiency; diabetes; 
malignat disease; rheumatoid 
arthritis or severe connective 
disorder; limited physical 
capacitg or immobility; 
infected or gangrenous ulcer; 
presence of ulcer < 2mon; 
admission to hospital likely to 
be required for > 10 days; 
pregnancy, lactation, 
inadequate contraception; life 
expectancy < 6mon. Mean 
Multiple interventions 
balanced between groups i.e. 
two ypes of compression 
evenly balanced between 
treatment and control groups. 
Gmup 1: (n=101) 
pentoxifyUine 1200mgin three 
divided doses daily, plus 
compression (either elastic 
single layer or 4 layer 
bandage). Group 2: ( ~ 9 9 )  
placebo plus compression. 
Treatment duration: 24 weeks 
Number healed at 24 weeks: 1. Complete healing = healingof 
65/101 (64.3%), 2. 52/99 all ulcers on reference leg. 
(52.5%). Global side effects: 1. 
3/101,2. 3/99. Withdrawals: 
11 in each aim. Reasons: side 
effects; no reason; patient 
hospitalised; exclnsiou criteria 
discovered after entry; 
medication omitted by patient 
(214 days); died. 
age: 1. 70.8 years, 2. 68.1 years. 
Median ulcer duration: 1 .6  
mon, 2.4mon. Median 
maximum ulcer diameter: 1. 
2.7 sq un, 2. 2.9 sq cm. 
Falanga, et al. RCT; 3 arm parallel group; 131 participants (129 analysed) 
(1999) double blind; matching in 14 centres; outpatient 
placebo clinics. Inclusion criteria: one 
or more venous ulcers ( > k m  
in diameter); venous disease; 
presence of reflux; age 18-90; 
ulcer duration 2-24mon; 
absence of significant arterial 
insufficienq (AB1 > 0.5); 
ambulatory; BM1 90.150% of 
ideal; able to give informed 
consent. Exclusion criteria: 
pregnancp, allergy to 
xanthines; lumber 
sympathectomy within last 3 
months; HbAlc > 10%, 
presence of dabetic or 
ischaemic ulcers; ulcers with 
exposed tendon or bone, 
infected ulcers needing 
systemic antibiotics, history of 
poor compliance with 
treatment. Mean Age: 1.60.4 
years, 2. 58.4 years, 3. 56.4 
years. Mean duration of ulcer: 
1. 6mon, 2. 6mon, 3. 6mon. 
Group 1: (n=45) placebo plus 
compression (Unna boot & 
elastic bandage). Group 2: 
(n=41) pentoxifyhe 1200mg 
in three divided doses daily 
plus compression. Group 3: 
( ~ 4 3 )  pentoxifyhe 2400mg 
in three divided doses daily, 
plus compression. Treatment 
duration: 24 weeks. 
Median time to healing: 1.100 
days, 2. 83 days, 3. 71 days. 
Number healed at 24 weeks 
(extrapolated from life- 
analysis): 1. 28/45 (63%), 2. 
31/41 (75%), 3.31/43 (73%). 
Global side effects: 1.13/45 
(29%), 2.9/41 (22%), 3.15/43 
(35%). Withdrawals: (n=32) 1. 
10/45,2.11/41,3.11/43. 
Reasons: not reported. 
Complete healing =healing of 
all ulcers on reference leg. 
Intention to treat analysis on 
all participants who enrolled, 
rece~ved aeatment and 
attended at least one follow-up 
visit, 129/131 enrolled. Study 
sponsored by drug's 
manufacturer. 
Mean ulcer size: 1. 9.63 sq cm, 
2. 11.43 sq cm, 3. 7.72 sq cm. 
MeanABI: 1. 1.1,2. 1.1,3. 1.1 
Schiinnann and RCT; 2 arm parallel group; 24 participants; setting not Group 1: (n=12) pentoxifylline Healing at 8 weeks: 1. 2/12 Mean ulcer size favoured 
Eberhardt (1986) single blind; placebo stated. Inclusion criteriano 1200mg daily plus (16%), 2. 3/12 (25%). Mean control at baseline. Type of 
stated. Exclusion criteria: compression. Group 2: (n=12) reduction in ulcer size (sq cm): compression not specified. 
takmgvasoactive drugs. Mean placebo plus compression. 1. 2.5 sq un, 2. 1.1 sq cm. Side Blindingnot described. 
ulcer size: 1. 5.4sq un, 2.2.5 effects: 1. 0/12,2. 2/12. Nil 
sq cm. No other data reported. Treatment duration: 8 weeks. withdrawals. 
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